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ABSTRACT OF THE DISSERTATION 
Leishmania parasites are the causative agent of leishmaniasis, a neglected tropical 
disease. An important aspect of Leishmania biology is asymptomatic parasite persistence, 
which typically occurs after clinical cure. Persistent parasites remain enigmatic despite 
their importance as reservoirs for transmission, having roles in maintaining protective 
immunity, and posing the risk of reactivation. I developed methods for assessing parasite 
replication by BrdU labeling and showed that persistently infected mice harbor two sub-
populations of L. major, one labeling similarly to acute-phase parasites, with the other 
showing much less labeling. That persistent parasite replication occurs without a 
commensurate increase in parasite number implies parasite killing. Continual parasite 
replication and destruction within antigen presenting cells provides an attractive model 
explaining the role of persistent parasites in maintaining immunity, namely through 
constant presentation of antigens derived from dead parasites and subsequent immune 
boost. While many of the persistent parasites are within host cells expressing high levels 
of iNOS, there is no apparent correlation between this and the parasite’s 
survival/replication status. Attenuated lpg2- L. major, a proposed model of parasite 
persistence, resemble WT persistent parasites for most parameters tested. However, more 
lpg2- parasites are associated with host cells expressing elevated levels of arginase 1, 
which further studies implicate as a negative correlate of immunity. While persistent 
parasites immunize their hosts against pathology from subsequent infection, experiments 
using marked parasites showed that persistently infected mice could be super-infected. 
This has implications for the generation of parasite phenotypic diversity, as genetically 
distinct parasites could be simultaneously transmitted to sand flies, the site of parasite 
 iii
sexual recombination. In addition to my studies of Leishmania persistence, I also 
identified markers that differentiate amastigote- from metacyclic-stage parasites, and 
used them to assay parasite differentiation within different host cell types in vitro. 
Although the markers were induced in the same sequence in all host cell types, the 
parasites in bone marrow-derived macrophages and dendritic cells were slower to lose 
LPG expression and resume replication. These data show that invading L. major can 
retain virulence factors, potentially playing a role in situations where parasites are 
transferred from one host cell to another. 
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Chapter 1 
 
Introduction 
 
 
This chapter was written entirely by M. Mandell. 
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Leishmaniasis, a neglected tropical disease 
‘Neglected diseases’ are defined as diseases that are not major focuses of the 
pharmaceutical industry despite great global demand for improved treatments and/or 
vaccines (1). The spectrum of diseases caused by infection with protozoan parasites of 
the genus Leishmania, collectively referred to as leishmaniasis, is a prime example of 
such a disease. Leishmaniasis is common throughout tropical, sub-tropical, and temperate 
regions of the Americas, Europe, Asia, and Africa, with an estimated 12 million people 
infected and more than 350 million people at risk (2). However, as the overwhelming 
majority of cases are amongst the very poor in the developing world, there is little profit 
motive for the development of new cures or preventative measures. 
The clinical manifestations of leishmaniasis are quite diverse, with different species of 
Leishmania or even by different isolates of the same Leishmania species causing 
drastically different pathologies (2). In general, there are three classifications of disease 
manifestations. The first is cutaneous leishmaniasis (CL), which is defined by non-life 
threatening skin lesions of varying severity. One species which causes CL is Leishmania 
major, the organism that is the focus of my work. The second major type of leishmaniasis 
is muco-cutaneous disease (MCL), which is the prevalent form of the disease in some 
parts of Latin America. MCL patients present first with a skin lesion at the site of 
Leishmania infection, but eventually develop lesions of the mucus membranes of the face 
that are very severe and disfiguring despite the fact that very few parasites are found in 
those lesions (2). The third disease manifestation is visceral leishmaniasis, in which 
parasites of L. donovani or L. infantum disseminate to the spleen and liver of infected 
patients and there replicate to high titers, resulting in disease that is fatal if untreated (2). 
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Perhaps a fourth classification of leishmaniasis could be “asymptomatic leishmaniasis” as 
most human infections with Leishmania result in asymptomatic persistent infections that 
last for the rest of the patient’s life (2). Although such infections may actually be 
beneficial under normal circumstances by conferring protective immunity against 
subsequent Leishmania infections (3), they pose a substantial risk of reactivation 
resulting in severe disease in the event that the patient becomes immunosuppressed (4). 
Reactivation has become a serious problem as the prevalence of HIV/AIDS has increased 
in regions in which leishmaniasis is common (5).  
Vaccines and treatments for leishmaniasis 
 There is currently no vaccine to prevent leishmaniasis caused by any Leishmania species 
(2). However, there is reason to hope that the development of such a vaccine might be 
possible, as CL patients with healed lesions are protected against pathology from 
subsequent infections (3). This knowledge is the basis for the centuries-old practice of 
leishmanization, in which live virulent parasites are intentionally infected into an 
inconspicuous site on the body such as the buttocks to protect against pathology in a 
more visible site. To date, many different vaccination approaches (e.g. live-attenuated 
parasites, recombinant parasite proteins, etc.) have been tried in a laboratory setting with 
varying success (6, 7).  
Several drugs are available to treat leishmaniasis, but all have serious drawbacks. The 
first drugs used against leishmaniasis are based on pentavalent antimony, and have been 
in use since the early 20th century. While reasonably inexpensive, antimony-based 
treatments are associated with serious side effects including death, and have lost efficacy 
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as the parasites in several parts of the world, especially India, have developed resistance 
(8). Other drugs available include miltefosine and liposomal amphotericin B. Miltefosine 
is associated with severe gastrointestinal side effects and teratogenicity and its efficacy is 
highly dependent on the Leishmania species/strain infecting the patient (2). Liposomal 
amphotericin B is a highly effective anti-parasitic agent, but is associated with serious 
side-effects and its cost is beyond the reach of most of the patients who are likely to need 
it (2). Because of these challenges, there remains great need for new treatment options.  
Overview of the Leishmania life cycle 
Leishmania parasites alternately infect sand fly and vertebrate hosts with transmission 
taking place as a result of the sand fly taking a blood-meal (Figure 1-1). Once in the sand 
fly, the parasites differentiate into the procyclic promastigote stage, which have relatively 
long flagella and express the multifunctional virulence factor lipophosphoglycan (LPG) 
on their surface. LPG mediates attachment of  these parasites to the sand fly midgut, 
preventing their excretion (9). Over the course of the next 10-14 days, the parasites 
replicate, undergo several developmental changes, detach from the midgut, and finally 
enter a G1 cell cycle arrest, becoming metacyclic promastigotes (10). Metacyclic-stage 
parasites are considered the transmissible form of the life-cycle, and consistent with this 
role, these parasites express virulence factors important for the establishment phase of 
vertebrate infection and are found within the mouth parts of the sand fly awaiting the next 
blood-meal (10). These parasites are then taken up by phagocytic immune cells and are 
eventually found within fusogenic phagolysosomes of macrophages, in which they 
replicate as amastigote-stage parasites. Amastigotes differ from metacyclics in several 
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ways, both in terms of their gene expression and morphology. Relative to metacyclics 
and other promastigotes, amastigotes are rounder and have much shorter flagella.  
In many “textbook” versions of the Leishmania life cycle, metacyclic-stage parasites are 
depicted as interacting exclusively with macrophages, and as such, most studies of the 
roles of Leishmania virulence factors have focused on macrophages. In reality, however, 
this is likely an over-simplification and parasites deposited into a host encounter several 
different host cell types in addition to macrophages, thus complicating the typical 
reductionist in vitro studies and raising questions as to their relevance to biology. In 
particular, neutrophils (PMNs) and dendritic cells (DCs) have been shown by two-photon 
microscopy studies to infiltrate the site of parasite inoculation within a few hours after 
infection, where they engulf the parasites (11-13). Interactions between metacyclics and 
these cell types may in fact predominate over metacyclic-macrophage interactions, 
necessitating a re-evaluation of the textbook description of the parasite life cycle and new 
studies of the virulence factors required for survival within and/or parasitism of PMNs 
and DCs.   
Although many or most parasites are found within PMNs and DCs shortly after 
inoculation, by 48 hours after infection most parasites at the inoculation site are found 
within macrophages (12). There are a number of models that could explain how this 
transfer occurs. One possibility is that the parasites within PMNs and DCs die and are 
cleared, leaving only those parasites that infected macrophages at 48 hours after 
infection. However, substantial evidence suggests that this is not the case as several in 
vitro studies have demonstrated parasite survival within PMNs and DCs, and the transfer 
of parasite-loaded PMNs into a naïve mouse yields a lesion comparable to the inoculation 
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of an equal number of free parasites (12, 14-17). Another possibility that is probably 
more relevant for DCs than for PMNs is that infected DCs could leave the inoculation 
site and migrate to the regional lymph node, resulting in infection of that tissue and 
leaving infected PMNs or macrophages at the infection site (11).  
A third model is that the parasites infect PMNs/DCs first and are subsequently transferred 
from these cells to macrophages. Under this scenario, the parasites could enter 
macrophages in one of two ways. The first involves the release of the parasite from an 
infected DC/PMN, and then the free parasite is engulfed by a macrophage. Consistent 
with this, two-photon microscopy studies identified instances in which infected PMNs 
appeared to die, releasing an intact parasite that appeared to then be taken up by another 
cell (12). While this sounds similar to what likely happens with amastigote-infected 
macrophages in which after several rounds of parasite replication the macrophage bursts 
releasing amastigotes that can then infect new macrophages, it is important to note that at 
48 hours after infection the parasites are unlikely to have had sufficient time to undergo 
substantial replication.  
The other way in which sequential infection could take place is by the macrophage 
engulfing the infected PMN/DC in what is referred to as the “Trojan horse” model of 
infection (16, 18). This model primarily deals with PMNs, which are very short-lived 
cells and that typically die by apoptosis. In this model, metacyclic-stage parasites enter 
PMNs and survive, even though their host cells ultimately undergo apoptosis. 
Macrophages are then recruited to the site of infection to clear the apoptotic PMNs, many 
of which contain viable parasites. Phosphatidyl serine on the surface of the infected 
apoptotic PMNs induces the macrophages to adopt a deactivated phenotype, thus 
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allowing safe entry for the parasite into its “preferred” host cell (18). Despite much effort, 
L. major entry into macrophages within PMN “Trojan horses” has not been observed in 
vivo (12, 13). However, macrophages have been observed to phagocytose apoptotic PMN 
that contain apparently intact Leishmania in vitro (14, 16).  
Regardless of the manner of parasite transfer from the first cell type infected to 
macrophages, one important question is whether the parasite undergoes differentiation 
within the host cell types that it encounters first and what stage of the parasite life cycle 
(metacyclic or amastigote) is encountered by the macrophage. This question has 
relevance for a number of temporally regulated virulence factors, including LPG, GP63 
and GP46, which are known to be important in the establishment-phase of mouse 
infections but are not expressed on amastigotes (19-23). If most parasites enter 
DCs/PMNs and differentiate into amastigotes prior to encountering macrophages, then 
macrophages would rarely encounter these virulence factors in vivo, and it is likely that 
they have evolved for interactions with other cell types. Alternatively, the parasites may 
retain the expression of these virulence factors as they transit through these cells allowing 
for the virulence factors to subsequently impact their interactions with macrophages. 
To date, the only data regarding the ability of the parasites to differentiate into the 
amastigote stage within non-macrophage host cells comes from studies of infected 
neutrophils, in which at least some of the parasites appear to remain in the metacyclic 
stage for up to 42 hours post-infection as assessed by retaining long, motile flagella (16). 
This study, however, made no mention of the percent of parasites with long flagella nor 
addressed other changes associated with differentiation such as the loss of promastigote-
specific virulence factors. In Chapter 2, I address whether L. major metacyclic-stage 
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parasites differentiate within dendritic cells, one of the other first cell types to encounter 
invading parasites, and for how long they retain the expression of the early virulence 
factor LPG. As part of these studies, I characterized five markers that are differentially 
expressed between amastigotes and metacyclics. Two of these were amastigote-specific 
antigens that are recognized by monoclonal antisera that were first generated by Charles 
Jaffe (24). The localization pattern of both of those antisera was particularly interesting, 
and is detailed in Appendix I.  
Leishmania major infections in mice 
The typical course of L. major infection in susceptible and resistant mice strains is shown 
in Figure 1-2. Following a either sand fly vector-mediated infection or needle inoculation 
of mice, L. major parasites replicate rapidly for several weeks in the absence of overt 
pathology in what is referred to as the ‘silent phase’ of the infection (25, 26). During this 
phase of the infection, the leishmaniasis-promoting IL-4 is the predominant cytokine 
produced by infection site-derived cells (25). In ‘susceptible’ BALB/c mice, IL-4 
production is maintained throughout the infection, resulting in Th2 polarization and, 
ultimately, fatal leishmaniasis (27). In contrast, in ‘resistant’ strains of mice such as 
C57BL/6, cells derived from the infection site begin to express the Th1 cytokines IL-12 
and interferon-γ co-incident with the inception of lesion pathology (4-5 weeks post-
infection) (25, 27). Ultimately, Th1-cytokine producing cells overwhelm IL-4 producing 
cells, leading to infected macrophages adopting a “classically activated” phenotype, 
which involves the expression of iNOS and subsequent generation of nitric oxide, a 
molecule that is essential for the control of Leishmania infection in mice (28-32). As a 
result, parasite number declines and the lesions eventually resolve ~12 weeks post-
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infection (26). Healed mice are then protected against pathology from subsequent L. 
major infections (33).  
Interestingly, despite the absence of pathology and the presence of this strong protective 
immune response, healed hosts continue to harbor a small, roughly constant number of 
viable parasites for the remainder of their life (34). These persistent parasites are 
important for several reasons. First, despite their limited numbers (~100 - 1000 in mice) 
(25, 35, 36) persistent parasites can still be transmitted to sand fly vectors, and as such, 
are a reservoir for the pathogen (26, 37). Second, as is the case with infected people, the 
parasites in persistently infected mice can “reactivate” in the event of 
immunosuppression, leading to severe disease (4, 29). Finally, they may be beneficial to 
hosts with intact immune systems because they help maintain protective immunity 
against pathology from subsequent Leishmania infections (38). In fact, treatment of 
persistently infected mice to achieve a sterile cure renders those mice susceptible to new 
infections (36). As described below, the focus of Chapters 3 and 4 is to better understand 
the biology of these persistent parasites. 
The biology of L. major persistence 
Asymptomatic persistence of Leishmania in their hosts, either in experimentally infected 
mice or in human patients, is a far more common result than sterile cure (34). Such 
infections are characterized by low parasite titers, the lack of pathology, and protective 
immunity against subsequent the pathology from infections. In fact, it is possible that the 
entry of the parasites into an asymptomatic persistent state may in fact be advantageous 
to the parasites, as they can still be transmitted from persistently infected hosts to new 
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sand flies (26, 39). Supporting this, when L. tropica parasites are transmitted by sand flies 
to their natural rodent hosts, these parasites directly enter a persistence-like state without 
inducing pathology (39).  
Despite their importance, both medically and in terms parasite biology, very little is 
known about persistent Leishmania, perhaps resulting from the fact that no in vitro model 
exists, and from the challenges associated with studying persistence in vivo (e.g. long 
infection times and low parasite numbers). On important unknown is whether or not 
persistent L. major replicate, as the number of persistent L. major remains relatively 
constant for the lifespan of its host (35, 40). Two models could explain this constant 
parasite population. One possibility is that the persistent parasites could be in a quiescent 
state that resists killing by the host. Alternatively, the parasites could replicate as in the 
acute phase, but their numbers do not increase as any replication is offset by parasite 
destruction. This second model is particularly attractive as it may help explain the 
requirement of persistent parasites to maintain immunity: constant presentation of 
antigens from killed parasites would serve to maintain the effector T cell population 
necessary for anti-Leishmanial immunity (41). Thus, a crucial question that I address in 
chapter 3 is whether or not persistent parasites replicate. 
It is clear from both clinical and laboratory studies that the host’s immune system is 
responsible for maintaining the parasites in an asymptomatic persistent state. Similar to 
what is seen when infected persons become immunosuppressed as a result of HIV/AIDS, 
persistent infections ‘reactivate’ in mice treated with inhibitors of iNOS or interferon-γ 
signaling, or in which CD4+ T cells have been depleted (29). 
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Although the host’s immune response clearly is involved in preventing the reactivation of 
persistent parasites, the parasites appear to be able to prevent it from completely clearing 
the infection. Two non-exclusive models have been proposed to explain how why sterile 
cure is not achieved. The first model to explain how Leishmania persist despite their 
host’s protective immunity against disease pathology is based on the finding that the 
immunomodulatory cytokine IL-10, along with immunosuppressive CD4+CD25+ 
regulatory T cells (Treg), are important for maintaining persistent infections, and that the 
blockade of IL-10 signaling or Treg depletion results in sterile cure of L. major-infected 
mice (36, 42, 43). IL-10 and Tregs are thought to facilitate parasite persistence by 
preventing host cell activation and iNOS expression, thus providing a safe niche in which 
the parasites can survive (36). 
 The second model is referred to as the “safe-cell” model (44). This model is based on the 
observation that the majority of L. major-infected iNOS-negative cells in persistently 
infected lymph nodes express fibroblast, but not macrophage, markers. In contrast, 
almost all infected macrophages from the same persistently infected tissue expressed 
iNOS (44). As the nitric oxide produced in iNOS-positive cells is lethal to Leishmania 
(29), it was proposed that these cells are sites of parasite destruction, while the fibroblasts 
are “safe cells” in which the parasites survive (44). Another candidate “safe cell” is the 
alternatively activated macrophage. These cells have been shown to support enhanced 
replication of L. major in vitro and in vivo as a result of their expression of arginase-I, 
which simultaneously blocks the formation of leishmanicidal NO while generating 
polyamines that the parasites can use for growth (45-47). Since first being proposed by 
Bogdan et al. in 2000 (44), the safe cell model has been cited 87 times, but neither the 
 12
study’s findings nor the proposed model have been independently tested. Thus one of the 
aims of chapter 3 is to test the safe cell model. One assumption of the model is that 
parasites should be found in safe cells such as fibroblasts or alternatively activated 
macrophages at all sites of persistence (i.e. the inoculation site and the draining lymph 
node). As Bogdan’s study focused exclusively on parasites within lymph node tissue, I 
sought to determine what types of host cells were infected at the footpad inoculation site 
to see if infection of proposed safe cells occurred at that site as well. Another assumption 
of the safe cell model is that iNOS-expressing macrophages are an unsafe cell in which 
persistent parasites would be killed. I therefore asked whether this assumption was 
correct or whether persistent parasites could survive within iNOS-expressing host cells.  
As mentioned above, persistent parasites are difficult to study, at least in part due to the 
long infection periods required to establish a persistent infection in mice. Interestingly, 
several parasite lines (including parasites lacking fructose-1,6-bisphosphatase or the 
nucleotide sugar transporter LPG2) have been generated that appear to directly enter a 
persistent-like state without first inducing pathology, suggesting that the parasite genes 
required for persistence differ from those required for virulence (35, 48). The LPG2 gene 
encodes a protein Golgi-localized GDP-mannose transporter which is involved in the 
synthesis of parasite virulence factors including phosphoglycans. Despite their long-term 
persistence in mice, these parasites appear incapable of replicating to high numbers and 
causing disease, as they are asymptomatic even in immunodeficient mice or in mice 
lacking iNOS (35). Nevertheless, they resemble WT persistent parasites in the number of 
viable parasites recoverable from infected mice and in the fact that lpg2- parasites are 
capable of generating and maintaining protective immunity against subsequent L. major 
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infections in some strains of mice (35, 49, 50). For these reasons, lpg2- and other “persist 
without pathology” parasites may be valuable both as models of Leishmania persistence 
and have potential as live-attenuated vaccine candidates if they resemble persistent wild 
type parasites (35). A final aim of the data presented in chapter 3 is to compare the 
replication and localization of lpg2- parasites in mice with what is seen with persistent 
wild type parasites.  
Leishmania, concomitant immunity, and evolution 
Because infected hosts are usually capable of developing an appropriate immune 
response, infection with Leishmania major is rarely fatal (51). Instead, mammalian hosts 
typically control the infection and heal. At the same time, while still harboring persistent 
parasites, they become protected against pathology from subsequent Leishmania 
infections: a condition known as concomitant immunity or premunition (52-54). 
Although the benefits to the host resulting from an effective anti-Leishmania immune 
response and subsequent immunity are obvious, there are likely also benefits to the 
parasite. One such benefit comes as a consequence of parasite persistence within a 
healthy host: the longer the host survives, the better the chances that the parasite will be 
transmitted (55-57).  
The term “concomitant immunity” is most commonly used in reference to infections with 
parasitic worms such as Schistostoma mansoni, where excrement from adult worms 
contains antigens that promote protective immunity against juvenile worms, which are 
the infectious forms of the worm’s life cycle. The adult worms are thought to benefit 
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from vaccinating their host against super-infection by eliminating intraspecific 
competition (52, 58).  
Another potential benefit to the pathogen comes if the host’s immune response is 
sufficiently strong to prevent super-infection, thus gaining for the first pathogen to infect 
the host exclusive transmission rights for its genome. A pathogen capable of such 
exclusive infection would have a strong selective advantage over those that could not, 
and the ability to generate exclusivity would likely spread quickly through a population, 
as has been proposed for lysogenic bacteriophage (59).  
In Chapter 4, I address whether the immunity maintained by persistent L. major is 
capable of generating ‘exclusivity’, or in other words, if the immunity maintained by 
persistent L. major is strong enough to prevent super-infecting parasites to establish their 
own persistent infections. In addition to being an important evolutionary question, this 
question has relevance for understanding the development and maintenance of 
Leishmania phenotypic diversity, as sterilizing immunity to re-infection would greatly 
diminish the chances of an infected host to pass on a mixed infection to a sand fly where 
parasite sexual recombination could take place (60).
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Figure legends 
Figure 1-1. The Leishmania life cycle. A. Sand flies are infected after taking a blood-
meal from an infected host. The parasites differentiate into procyclic promastigotes, 
which are retained in the sand fly’s midgut via interactions between parasite LPG and 
receptors on the sand fly’s intestinal epithelium. B. Parasites eventually detach from the 
midgut and develop into infectious metacyclic-stage parasites, which are found in the 
mouthparts of the sand fly awaiting the next blood-meal. C. Metacyclic-stage parasites 
are deposited into the dermis of their mammalian host, where they interact with several 
different types of host cells including macrophage, dendritic cells, and neutrophils. D. 
Ultimately, parasites are found as amastigote forms in acidified phagolysosomes of 
macrophages. E. Parasites replicate within phagolysosomes eventually resulting in the 
lysis of the macrophage and the release of amastigotes which can either go on to infect 
new macrophages or be ingested by a biting sand fly, completing the cycle.  
Figure 1-2. The course of L. major infection in susceptible and resistant mouse strains. 
Both graphs. Black lines represent parasite number, grey lines represent lesion pathology. 
Parasite numbers increase dramatically during the first ~4 weeks after infection in the 
absence of pathology in what is termed the ‘silent phase’ of infection.  Top graph. 
Infection of ‘susceptible’ BALB/c mice results in Th2 skewing associated with 
uncontrolled parasite growth and eventually fatal leishmaniasis. Bottom graph. Infection 
of ‘resistant’ C57BL/6 mice results in Th1 skewing, associated with lesion healing and a 
decrease in parasite number starting 6-8 weeks post infection. Lesions typically heal 12-
15 weeks after infection. Healed mice are immune to subsequent L. major infections and 
continue to harbor ~1000 parasites for the remainder of their lives (persistent phase). 
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Abstract 
Many workers have proposed that neutrophils and dendritic cells (DCs) are the 
predominant cell types first engulfing Leishmania following the transmission of 
metacyclic parasites by a sand fly bite. Following entry into such ‘transit’ cells, parasites 
are ultimately transferred to the macrophage, although some parasites likely enter 
macrophages directly as well. This raises the question as to whether parasite virulence 
determinants whose functional roles are restricted to the earliest phases of establishment 
of Leishmania infection persist long enough in transit to play significant roles in the 
macrophage. One of such early-acting virulence factors include the most abundant 
parasite surface molecule, lipophosphoglycan (LPG). We first identified a set of 
experimental ‘landmarks’ that clearly differentiate infective metacyclic promastigotes 
from replicating macrophage amastigotes; these markers show an orderly transition post-
infection, allowing the tempo and properties of parasite differentiation to be visualized 
microscopically. In peritoneal macrophages, loss of promastigote flagella and expression 
of amastigote differentiation markers occurs within 12 hr, followed by entry into the cell 
cycle as assessed by BrdU incorporation after 24 hr. LPG levels declined such that by 48 
hr it was undetectable on most parasites. Bone marrow derived macrophages or DCs 
maintained a similar sequence of marker transitions, but with different kinetics for some 
but not all markers, and with fewer parasites showing evidence of replication even by 72 
hr, suggesting overall a slower rate of differentiation to amastigotes. Notably LPG was 
lost much less rapidly in both DC and BMM, maintaining levels as high as that seen in 
metacyclics in 37% percent of the parasites after 72 hr, well beyond estimates of the 
‘transit’ time to macrophages. While these LPG+ parasites have not re-entered the cell, 
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they otherwise resemble amastigotes and therefore present an intermediate phenotype.  
These data suggest that LPG and potentially other ‘early’ virulence factors would have 
the opportunity to impact macrophage function through either the transit or direct route, 
potentially facilitating parasite establishment.  
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Introduction 
Leishmaniasis, caused by protozoan parasites of the genus Leishmania, is considered a 
neglected tropical disease because there is a lack of good treatment options despite many 
millions of people at risk of infection (1). Leishmania parasites are transmitted to their 
mammalian hosts by the bite of an infected sand fly which deposits non-replicating, 
flagellated metacyclic-stage parasites into the dermis while taking a blood meal. Once in 
the dermis, the parasites interact with phagocytic cells of the immune system, and are 
eventually found within lyososome-like vacuoles in macrophages where they replicate 
intracellularly as non-motile amastigotes.  
Although many in vitro studies have focused on interactions of infectious parasites with 
macrophages, recent in vivo data suggest that other cell types, in addition to 
macrophages, also encounter and engulf invading metacyclic-stage parasites. These 
include neutrophils and dendritic cells (DCs), which are rapidly recruited to the infection 
site and collectively may predominate over macrophages as the first host cells for 
Leishmania (2, 3). However, by 24-48 hours after infection, the percentage of L. major 
within these cell types declines, such that at later time points macrophages are the 
predominant cell type infected (2-4). How this transfer of the parasite from the first cell 
type infected to macrophages is under debate, but presumably parasites are either 
released from the infected cell and subsequently taken up by a macrophage or, 
alternatively, the infected cell itself is engulfed by a macrophage (5).  
Regardless of the manner of parasite transfer, an important question is whether the 
parasite undergoes differentiation within its cells of first contact and what stage of the 
parasite life cycle (metacyclic or amastigote) is encountered by the ‘destination’ 
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macrophage. The answers to these questions could have profound consequences to our 
understanding of the role of parasite virulence factors, especially those known to function 
early in the initial stages of establishment of intracellular parasitism. A number of 
parasite virulence factors such as lipophosphoglycan (LPG), GP63, and GP46 are 
temporally regulated and not expressed by amastigotes despite having important roles in 
the establishment of infection by metacyclic-stage parasites (6-10). Thus, invading 
metacyclic-stage parasites could be taken up by ‘transit’ host cells such as neutrophils 
and/or DCs, undergo differentiation and cease expression of these ‘early’ virulence 
factors prior to their transfer into macrophages. Under this scenario, macrophages would 
not encounter ‘early’ virulence factors in natural infections. Alternatively, the parasites 
could retain expression of the ‘early’ virulence factors throughout the transit period until 
they reach a macrophage, thus retaining the armamentarium of virulence factors for 
deployment within the macrophage. Virulence factor retention could be mediated by a 
variety of mechanisms, for example specific control of early virulence factor expression 
or more global mechanisms such as delayed or even arrested differentiation in the transit 
PMN/DC. 
As an example of an ‘early’ virulence factor, we focused on the surface promastigote 
glycoconjugate, lipophosphoglycan (LPG).  LPG is the most abundant molecule on the 
surface of invading metacyclic-stage parasites (6).  Experiments with genetically-
modified Leishmania lacking genes essential for LPG synthesis have demonstrated that 
LPG plays key roles in parasite survival upon infection of macrophages, including 
prevention of lysis by complement, protection against oxidants, and transiently inhibiting 
phagolysosomal fusion (7-10). In addition, LPG has been shown to be important in 
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protecting L. donovani parasites from killing by neutrophil extracellular traps (11), and in 
establishing a safe niche for these parasites facilitating their survival within neutrophils 
(12). 
To address the question of whether L. major metacyclics differentiate into amastigotes 
within the cells types of ‘first contact’ and how long the expression of LPG is retained as 
the parasites transit through these cells, we identified a set of markers suitable for 
immunofluorescence microscopy that would allow an assessment of the differentiation 
status of Leishmania following host cell uptake. These included markers expressed by 
metacyclic promastigotes but not amastigotes such as the flagellum, employing 
paraflagellar rod proteins (13), and markers expressed by amastigotes but not metacyclic 
promastigotes (unknown antigens recognized by antisera T17 or T18) (14), activation of 
amastigote gene expression (SSU:YFP), and replication (BrdU incorporation). We 
compared the expression of these markers in peritoneal and bone marrow macrophages 
(BMMs) first, in order to establish a baseline for macrophage differentiation. For these 
studies, peritoneal macrophages (PEMs) serve as our gold-standard host cell because 
parasites are known to enter these cells and become replicating amastigotes by 72 hours 
post-infection (7, 15, 16). We then studied the expression of the stage-specific markers in 
dendritic cells, one of the first cell types to be infected in vivo (2). In all three cell types, 
we found that the markers of ‘amastigotigenesis’ were induced in the same order, with 
amastigote marker induction occurring prior to the onset of parasite DNA synthesis. We 
then used similar approaches to assess LPG level, and showed that even after 72 hr within 
DCs a high fraction of intracellular parasites retained high levels of LPG. As this is well 
beyond the estimated transit time of Leishmania through DCs in the literature (~24 hr), 
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these data establish that the destination macrophages will encounter a significant number 
of Leishmania retaining LPG at biologically relevant levels able to mediate virulence 
functions characterized previously in macrophages.    
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Materials and Methods 
Parasite strains and culture 
L. major Friedlin V1 strain (MHOM/IL/80/Friedlin; abbreviated as LmjF) parasites were 
grown at 26˚C in M199 medium (US Biologicals) supplemented with 40 mM 4-(2-
hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) pH 7.4, 50 μM adenosine, 
1 μg ml−1 biotin, 5 μg ml−1 hemin, 2 μg ml−1 biopterin and 10% (v/v) heat-inactivated 
fetal calf serum (17), in some cases containing selective drugs. LmjF parasites expressing 
YFP (yellow fluorescent protein; SSU:IR1PHLEO-YFP) were described elsewhere (18). 
L. major LV39cl5 lpg1- were described previously and (19) were cultured in the above 
media supplemented with 2 mM L-glutamine, 9 µg ml-1 folate and RPMI Vitamin Mix 
(Sigma). Infective metacyclic-stage parasites were recovered using the density gradient 
centrifugation method (20). Prior to infection of host cells, purified metacyclic-stage 
parasites were opsonized with serum from C5-deficient mice.  
Mammalian host cells 
Cells were isolated from female C57Bl/6J mice (6-10 weeks old; Jackson Labs). 
Peritoneal macrophages (PEMs) were elicited by a peritoneal injection of potato starch 
and harvested and maintained in DMEM (Invitrogen) containing 10% FCS and 2 mM L-
glutamine as described  (21). Bone marrow-derived macrophages (BMMs) and dendritic 
cells (DCs) were harvested as describe previously (22). Briefly, bone marrow was flushed 
from the femurs of mice and cultured in dendritic cell or macrophage growth media at 
37˚ for 6 days.  DCs were cultured in RPMI media without L-glutamine (Gibco) 
supplemented with 10% fetal calf serum (Hyclone), Glutamax (Gibco), Na pyruvate, non-
essential amino acids, and kanamycin (DC media) with the addition of 2% GM-CSF.  
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BMMs were cultured in DMEM (Gibco) supplemented with 10% fetal calf serum, 5% 
horse serum, Glutamax (Gibco), Na pyruvate, non-essential amino acids, and kanamycin 
(as described above for the macrophage media) with the addition of 30% L-cell media as 
the source of M-CSF.  For infections, cells were cultured in DC or macrophage media 
without growth factors. Prior to infection, PEMs, DCs, and BMMs were adhered to 
sterile glass coverslips in 24 well dishes overnight. 
Infection of host cells 
Parasites were added to host cells at a ratio of 5:1. Typically, extracellular parasites were 
removed by extensive washing 2 hours after parasites were added to host cells. Infected 
cells were maintained in the media described above, which was changed daily for the 
duration of the experiments. For DNA labeling studies, containing 0.1 mM 5-bromo-2'-
deoxyuridine (BrdU; Sigma) or 0.1 mM 5-ethynyl-2’-deoxyuridine (EdU; Life 
Technologies) was added for the duration of time indicated in the text.  
Antibodies 
L. major nuclei were detected with a pool of rabbit antibodies raised against L. major 
histones H2A, H2Avariant, H2B, H3, and H4 (Wong and Beverley, in preparation).  Were 
pooled at a ratio of 3:2:3:3:1 by titer as determined by Western blot and used at a dilution 
of 1:750 (Wong and Beverley, in preparation). BrdU was detected with a rat monoclonal 
antibody (Abcam) used at 10 μg ml−1. For dual-labeling experiments involving YFP, 
Alexafluor488-conjugated rabbit anti-GFP antisera (Invitrogen) was used at a 
concentration of 8 μg ml−1.  The amastigote-specific mouse monoclonal antisera T17 and 
T18 were a gift from Charles Jaffe (Hebrew University) and were diluted 1:400 (14). 
Paraflagellar rod (PFR) was detected with the mouse monoclonal antibody L8C4 
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(provided by Keith Gull), and was used at a dilution of 1:50 (13). Lipophoshoglycan 
(LPG) was detected using two different antisera. For most experiments, Gal-substituted 
LPG was detected with the mouse monoclonal antibody WIC79.3 (23), which was used 
at a 1:250 dilution. Where specified, “metacyclic LPG”, in which most of the galactose 
side chains are capped with arabinose, was detected with the mouse monoclonal antibody 
3F12 (23), used at a 1:100 dilution.  
The following fluorescent secondary antibodies were used: Alexafluor488 goat anti-
rabbit, Alexafluor555 goat anti-rabbit, Alexafluor633 goat anti-rabbit, Alexafluor488 
goat anti-mouse, Alexafluor594 goat anti-mouse, and Alexafluor488 goat anti-rat 
(Invitrogen, all used at a concentration of 2 μg ml−1).  
Immunofluorescence staining and confocal microscopy 
At the designated time points, samples were fixed in 4% (w/v) paraformaldehyde in 
phosphate-buffered saline (PBS) for 10 minutes. Samples were washed in PBS, and then 
blocked and permeabalized in PBS containing 5% (v/v) normal goat sera (Vector labs) 
and 0.1% (v/v) Triton-X-100 for 30 min. The samples were then stained with various 
combinations of primary antibodies (as described in the text) for 1 h. Unbound antibody 
was then washed off in PBS and primary antibodies were detected with combinations of 
fluorescent secondary antibodies (as described in the text) for 40 min, followed by a 
second wash in PBS. In experiments involving BrdU, fixed samples were washed with 
distilled water prior to a 40 minute incubation in 2 N HCl. Samples were then extensively 
washed in PBS prior to blocking and permeabilization as described above. Samples were 
incubated in anti-BrdU antisera for 2 hours. For experiments involving EdU, we labeled 
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the EdU according to the manufacturer’s protocol (Life Technologies) prior to antibody 
labeling.  
Following staining, all samples were mounted in ProLong Gold (Invitrogen). All 
microscopy was performed on a Zeiss 510 META confocal laser scanning microscope.  
Cutoffs for saturation and background levels were adjusted with Photoshop software 
(Adobe).  
Quantitation of LPG abundance 
Samples were stained to detect parasite histones and PGs and confocal microscopy 
performed as described above. 3-dimensional confocal image stacks were then 
compressed into a single 2-dimensional image which was then used for subsequent 
analysis. For samples harvested less than 24 hours post infection, at which time the 
parasite’s outline could be visualized with WIC79.3 staining, Volocity software 
(Improvision) was used to trace the outline of the parasites and then measure the sum of 
the WIC79.3 (red) intensity within the traced area. For samples harvested 24 hours or 
later after infection, this method was unusable because the outline of the parasites was 
increasingly invisible. Thus, we measured the sum of WIC79.3 intensities within a 44.8 
µm2 circle centered at the parasite nucleus. We did not use this method with parasites at 
time points prior to 24 hours because a circle is a poor approximation of the elongated 
shape of metacyclic-stage parasites.  
Statistics 
Unless stated otherwise, the data reported throughout the paper is the mean of at least 
three independent experiments in which >400 parasites were scored per experiment. Data 
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are presented as the mean ± the standard deviation. P values were determined either by a 
Student’s t-test or a Chi-square test. 
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Results 
Characterization of differentiation markers and their expression following L. major 
infection of peritoneal macrophages  
First we sought markers that clearly distinguished L. major metacyclic parasites from 
authentic amastigotes, obtained after 120 hr infection of peritoneal macrophages in vitro, 
or visualized in sections taken from mice infected for several weeks. While a number of 
genes showing quantitative differences in promastigote or amastigote expression are 
known from microarray or proteomic studies, few show qualitatively on/off properties 
suitable for use in characterization of the tempo of amastigote differentiation on a cellular 
level (24-29). We explored a number of candidates, and ultimately identified five suitable 
for use.  As shown in Fig. 1, these clearly distinguish between metacyclic-stage parasites 
and parasites 72 hours after infection of peritoneal macrophages (PEMs), a time at which 
many of the parasites in these cells are replicating amastigotes (below).  
As a marker ‘on’ in promastigotes and ‘off’ in amastigotes, we chose the expression of 
the paraflagellar rod protein PFR1, which accompanies the loss of the flagellum during 
differentiation (Figure 1A) (30).  As markers ‘off’ in promastigotes and ‘on’ in 
amastigotes, we followed the expression of the amastigote-specific antigens recognized 
by the monoclonal antibodies T17 and T18 (14). The epitopes recognized by the two 
antisera clearly differed in their cellular localization within amastigotes, suggesting they 
recognize different amastigote molecules. A third such marker consisted of a YFP 
transgene inserted into the ribosomal SSU locus, where YFP is “off” in metacyclic 
promastigotes but “on” in other stages (Figure 1D). While the mechanism controlling the 
YFP transgene expression have not been definitively established, preliminary studies 
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suggest that the reduction in YFP fluorescence and protein results from a decrease in YFP 
mRNA abundance (data not shown). Lastly, we monitored parasite DNA synthesis 
following metabolic labeling with BrdU or EdU (31, 32), to detect the transition between 
non-replicating metacyclics and replicating amastigotes.   
Sequence and timing of metacyclic/amastigote differentiation marker expression.   
We compared the sequence and timing of amastigote marker induction in PEMs. These 
results are summarized in Fig. 1E. The first marker change was the loss of reactivity with 
anti-PFR1 antisera. By 4 hours after infection (the earliest time point attempted), most 
parasites had lost anti-PFR staining (89 ± 6%), and by 24 hours essentially no parasites 
(0.2 ± 0.6%) were recognized with this antibody. Interestingly, loss of PFR1-reactivity 
did not completely coincide with the disappearance of long flagella, as staining with anti-
phosphoglycan antisera or mAb T17 (see below) revealed that some parasites retained 
long flagella even at 24 hours post-infection (data not shown). 
Next we observed that reactivity with mAbs T17 and T18 rapidly appeared. At four hours 
after infection, a small percentage of parasites (<5%) were weakly reactive with either 
MAb, but by 8 hours post-infection 37 ± 7% and 41 ± 12% were positive for T17 or T18 
reactivity, respectively (Fig. 1E).   By 11 hours after infection, >90% of the parasites 
were recognized by these antisera, and at 24 hours post infection, 94 ± 4% of the 
parasites are T17+ and 92 ± 8% are positive for T18 reactivity.   
SSU:YFP transgene expression first became weakly detectable 8 hours after infection, 
with 18 ± 3% of the parasites YFP+ at 12 hours post-infection. By 24 hours, the 
percentage of YFP+ parasites had increased to 51 ± 13%. Interestingly, while the percent 
of parasites displaying YFP fluorescence continued to increase reaching 70 ± 17% at 72 
 42
hours post-infection, it never became 100%.  Similarly, only ~70% of parasites within 
infected mouse footpads were YFP+ 2 weeks following infection, a time of vigorous 
parasite replication and expansion. Currently we do not understand why 100% YFP 
expression is not attained. 
The last marker transition was the commencement of DNA replication. While all other 
markers had achieved ‘full’ expression by 24 hr (PFR off, T17, T18, and SSU:YFP on), 
only 8 ± 1% of the parasites showed labeling with anti-BrdU antisera at this time. The 
percentage of BrdU-positive parasites increased such that at 72 hours post-infection, 72 ± 
13% of the parasites were BrdU+. Together, these data show that the amastigote markers 
are induced in an orderly sequence with promastigote-specific PFR1 gene expression 
turning off by 4 hr post-infection, T17 and T18 expression turning on by 8-11 hr, 
SSU:YFP expression turning on by 11-24 hr, and finally replication commencing around 
24 hr (Fig 1F). While we did not seek to rigorously establish whether various markers 
appeared homogeneously in sequence, the quantitative aspects suggest that this is likely. 
This supposition was supported by limited preliminary tests examining co-expression 
(not shown).   
These data establish a useful developmental sequence of marker expression for analysis 
of Leishmania differentiation. Whether these transitions are functionally connected or 
interdependent, or occur independently of one another, has not been investigated.  
Amastigote marker induction in bone marrow-derived macrophages and dendritic cells 
We then examined the ‘differentiation sequence’ markers above in L. major metacyclic 
infections in two other cell types, bone marrow-derived macrophages (BMM) or dendritic 
cells (DCs). These data are plotted for each marker separately for the three cell types in 
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Fig. 2, or by cell type in Fig. 3 (BMM) and Fig. 4 (DC). Overall, the relative order of 
developmental marker expression was conserved amongst the three cell lines, albeit with 
a few differences amongst specific markers and in the overall rate. 
Loss of anti-PFR1 reactivity in BMM and DCs was similar to what is seen in PEMs at 
either 4 or 24 hours post-infection (P > 0.17 by Student’s t-test; N = 3 experiments) with 
35 ± 25% and 0.5 ± 0.6% of parasites in BMMs and 15 ± 13% and 0.4 ± 4% of parasites 
in DCs labeling at these time points (Figure 2A). The induction of T18 reactivity and 
SSU:YFP fluorescence also showed similar time courses in the three cell types (P > 0.16 
for T18 and P > 0.2 for YFP by Student’s t-test; N = 3 experiments; Figs. 2B and 2C). 
Induction of T17 reactivity appeared to be slower in BMMs than in PEMs in that a lower 
percentage of the parasites at 8 hours post-infection were T17+ (10 ± 8%, P < 0.01 by 
Student’s t-test; N = 3 experiments). This difference disappeared by 24 hours, with 89 ± 
10% of the parasites within BMMs showing T17-positivity. With the T17 marker, 
parasites within DCs were intermediate between the profile seen for PEMs and BMMs, 
but were not significantly different from the PEM results (P > 0.08 by Student’s t-test; N 
= 3 experiments; Figure 2D). Lastly, parasites within BMMs and DCs also did not initiate 
DNA synthesis until after 24 h, as measured by BrdU-incorporation, as only 8 ± 2% of 
parasites within DCs and 5 ± 4% of parasites within BMMs were positive at 24 h.  At 72 
hours post infection significantly fewer parasites within DCs (46 ± 9%; P = 0.02 by 
Student’s t-test; N = 3 experiments) and BMMs (35 ± 15%; P = 0.01 by Student’s t-test; 
N = 3 experiments) are BrdU+ than is seen in PEMs (72 ± 13%; Figure 2E).  
When plotted by cell type, it is evident that the parasites show a similar progression in 
developmental marker expression in all three cell types (Fig. 1E, 3, 4).   For the most part 
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the timing of marker expression was also conserved, other than reduced numbers of 
parasites entering the cell cycle in BMM and DCs relative to PECs (Fig 2E).     
Quantitation of LPG expression. 
LPG expression was assessed at different time points after infection of PEMs by its 
reactivity with the phosphoglycan (PG) specific monoclonal antibody WIC79.3, which 
recognizes galactose modifications of LPG and proteophosphoglycan (PPG) (23). While 
these modifications are often capped by arabinose in “metacyclic” LPG in L. major, we 
have shown previously that >90% of metacyclic parasites enriched through the gradient 
centrifugation protocol performed here retain some level of non-capped Gal-residues (20, 
23), and thus are detected by this antibody. While PPGs also react with WIC79.3, they 
are expressed at much lower levels than LPG (<1%) (19).  
First LPG expression was assessed qualitatively, scoring parasites as either “LPG-
positive” or “LPG-negative”. By this assay, 99 ± 1% of metacyclic stage parasites were 
LPG+. By 24 hours after infection of PEMs, this number had declined to 81 ± 2%, and by 
72 hours post infection, only a few (5 ± 3%) of the parasites had detectable LPG. 
Preliminary experiments monitoring the presence of arabinose-capped metacyclic-
specific LPG using the monoclonal antibody 3F12 (23), yielded comparable results with 
a modest increase in the percentage of 3F12-negative parasites by 24 hours after infection 
and almost complete loss of 3F12+ parasites by 72 hours post infection (Supplemental 
figure S1).  
The intensity of WIC79.3 reactivity was then used to quantitate LPG expression per cell 
(Figure 5A). To establish the background we used the LPG-deficient lpg1- mutant 
described previously (19). By this assay, all metacyclic parasites show LPG expression, 
 45
with a mean labeling intensity of 45,900 ± 23,300 arbitrary units (see the Methods for the 
procedure used for delineating parasite boundaries and the intensity of binding). 
Interestingly, at 20 minutes post infection the mean per-cell WIC79.3-reactivity increases 
to 66,100 ± 24,500 units. Thereafter, LPG expression gradually declined (albeit with 
some heterogeneity) such that at 48 and 72 hours post infection, the parasites reach 
background levels of WIC-reactivity (below 20,000 units). Consistent with the results 
from the qualitative assay a few (5-10%) of the parasites at 48 and 72 hours post infection 
retained detectable WIC79.3-reactivity, which in some cases was as high as seen in 
metacyclics. Thus, LPG is no longer present at significant levels on most parasites by 48 
hours post infection of PEMs.  
High levels of LPG retained on parasites in BMMs and DCs 
We then examined LPG expression following infection of L. major metacyclics of BMM 
and DCs (Figs. 4B-D). At 24 hours post-infection, 19 ± 2% of parasites within PEMs 
have lost LPG expression by the qualitative assay described above.  In contrast, fewer 
parasites in BMMs (8 ± 5%; P < 0.05 by Student’s t-test; N = 3 experiments) lost LPG 
expression at this time point, with the parasites in DCs yielding a result intermediate 
between the two types of macrophages (12 ± 6% LPG-negative). The most striking 
difference was seen at 72 hr; while 95 ± 3% of parasites within PEMs are LPG- at 72 
hours after infection, many parasites in both BMMs and DCs retained LPG expression at 
this time point, with 65 ± 5% of parasites in BMMs (P < 10-4 by Student’s t-test; N = 3 
experiments) and 37 ± 14% (P < 0.02) of parasites in DCs retaining high levels of LPG 
(Fig. 5B and C).  
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We then measured LPG expression per cell on all three types at 24 and 72 hr (Fig. 5D).   
Consistent with the results from the qualitative assay described above, parasites within 
BMMs and DCs retained LPG expression for a longer period of time. Whereas the mean 
per-cell WIC79.3 intensity of parasites within PEMs 24 hours after infection was reduced 
by ~30% relative to that of metacyclic stage parasites (P < 0.001 by Student’s t-test; N = 
3 experiments), the mean LPG levels in parasites within BMMs and DCs had not 
declined significantly, remaining above 41,300 units. By 72 hours, however, this value 
did decline for parasites within DCs and BMMs, which had mean LPG expression of 
24,900 ± 15,400 and 28,600 ± 19,200 units, respectively. At 72 hr however many 
individual parasites within both BMMs and DCs showed little LPG expression, similar to 
that of the lpg1- LPG negative parasites.  Nevertheless, the mean WIC79.3 intensity of 
parasites within PEMs at 72 hours after infection was 17,600 ± 8,400 units, significantly 
less than that for parasites within either BMMs or DCs (P < 10-5 by Student’s t-test; N = 3 
experiments). Importantly, even at 72 hours post-infection, many of the parasites that 
were classified as “LPG+” showed LPG expression comparable to metacyclic-stage 
parasites. This suggests that a population of parasites within BMMs and DCs retained 
biologically relevant amounts of LPG for at least 72 hr in BMM and DCs, but not PECs.  
LPG-retaining parasites within bone-marrow dendritic cells are non-dividing 
We asked whether the sub-population of cells retaining high levels of LPG after 72 hr 
following infection of BMM or DCs had initiated DNA synthesis or not. For these 
experiments, we made use of the Click-iT EdU system (Life Technologies, to facilitate 
simultaneous visualization of LPG and the incorporation of thymidine analogue (EdU) 
into parasite DNA. DCs were infected with L. major metacyclics and then cultured in the 
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presence of EdU for 72 hours, after which the samples were fixed and stained to 
simultaneously detect L. major histones, LPG, and EdU. For these studies, the results 
obtained for the percent of parasites that were labeled with EdU were in the ballpark of 
the results described above with BrdU. We imaged a total of 1174 parasites, 38% of 
which were EdU+ and 21% of which were LPG+ (Figure 4A). Assuming that there is no 
relationship between a parasite’s LPG-positivity and DNA synthesis, as a null hypothesis 
we would expect that 38% of the LPG+ parasites should be EdU+. Instead, while 46% of 
LPG- parasites are EdU+, only 7% of the LPG+ parasites are EdU+, significantly less than 
what would be expected (p < 10-30 by a Chi-square analysis, N = 2 experiments, 1174 
parasites; Figure 4B).  
Thus, the parasites within DCs retaining high levels of LPG expression have not yet 
entered the cell cycle. This finding raises the question as to whether the loss of LPG and 
the induction of DNA synthesis is an ordered process. To address this, we performed the 
same experiment as above, only this time on PEMs 24 hours post-infection, a time point 
at which most parasites retain LPG expression and in which some parasites have become 
BrdU-positive (see Figure 1F). Unlike in DCs at 72 hours post infection, in PEMs at 24 
hours post-infection a similar percentage of LPG+ and LPG- parasites are EdU+, 
suggesting that LPG loss and DNA synthesis are not ordered in PEM infections (p = 0.41 
by a Chi-square analysis; N = 2 experiments, 1255 parasites; Figure 4B). 
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Discussion 
Amastigote development in peritoneal macrophages 
Although the primary aim of our study was to address parasite differentiation and LPG 
loss within DCs, we first had to characterize the differentiation process within 
macrophages, cells in which the parasites are known to differentiate. These studies were 
carried out within starch-elicited peritoneal macrophages, which represent our gold-
standard host cell type because they are permissive to all of the stages of parasitism 
(entry, differentiation, and parasite replication). Some of the developmental changes 
associated with amastigogenesis, such as the loss of PFR expression, happened very 
rapidly upon parasite infection of these cells, with more than 90% of the parasites 
displaying a PFR- phenotype by 4 hours post-infection. Other developmental changes as 
assessed by amastigote markers occurred later, with T17 and T18 reactivity being the 
next “markers” to be induced, followed by the induction of YFP fluorescence. The 
findings that the induction of amastigote markers appears to occur in an ordered manner 
is consistent with the ordered progression of gene expression changes seen by microarray 
studies as L. donovani differentiates in axenic culture (27). These changes preceded re-
entry into the cell cycle, as they had largely gone to completion by 24 hours post 
infection, a time point at which only 8% of the parasites were BrdU+.  
All of the amastigote markers are induced on parasites within DCs 
 Having established the timing and sequence of amastigote marker induction within 
PEMs, we then asked whether L. major metacyclic-stage parasites behave similarly 
within DCs, one of the host cell types with which parasites interact first upon infection in 
vivo and which may be important either as hosts for or killers of parasites and have 
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important roles in the establishment of either protective or pathological immune 
responses (2, 33-35). As a control for these studies, we also assessed the differentiation of 
the parasites within bone marrow-derived macrophages (BMMs) in order to better 
understand the range of parasite differentiation phenotypes in different types of 
macrophages. Parasites within BMMs and DCs clearly did not remain metacyclics, as 
they became PFR-, T17+, T18+, and YFP+ in a manner similar to that of parasites within 
PEMs. In addition, by 24 hours after infection, a comparable percentage of the parasites 
within BMMs and DCs were BrdU+. Thus, at this time point each amastigote marker is 
present on at least a few parasites, consistent with at least partial if not complete 
differentiation within DCs.  
Fewer parasites in BMMs and DCs undergo DNA synthesis or lose LPG expression 
Although all amastigote markers were present on parasites within DCs and BMMs, 
significantly fewer of the parasites within these cells became BrdU+ or LPG- by 72 hours 
post-infection than what is seen in PEMs. Importantly, these LPG+ parasites likely have 
biologically relevant levels of LPG, as quantitation demonstrated that they express 
comparable amounts of LPG to metacyclic-stage parasites on a per-cell basis. Dual-
labeling experiments showed that the LPG+ parasites in DCs at this time point tended to 
be preferentially BrdU-, suggesting that the parasites with residual LPG were not 
replicating. Nevertheless, we argue that the LPG+ parasites are viable for several reasons. 
First, while killed intracellular Leishmania are degraded very quickly by host cells (36), 
the LPG staining of the parasite’s surface revealed that the LPG+ parasites appeared 
intact and morphologically normal. In addition, in BMMs where 65% of the parasites are 
LPG+, we saw that 66% of total parasites showed bright YFP fluorescence, implying that 
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at least some of the LPG+ parasites were positive for endogenous YFP fluorescence. Such 
fluorescence would be lost in killed parasites arguing that LPG+ parasites are alive (37).  
Taken together, these results demonstrate that in bone marrow-derived DCs and 
macrophages, a population of parasites exist up to 72 hours after infection which have a 
phenotype that is intermediate between metacyclics and amastigotes. Similar to 
amastigotes, they are PFR-, T17+, T18+, with some being YFP+. However, they express 
levels of LPG similar to what is seen on metacyclic stage parasites and have not resumed 
replication. Such intermediate phenotypes could arise either because amastigogenesis is a 
slower process within BM-derived cells or alternatively the parasites could instead be 
arrested in some intermediate stage in development. Further studies will be required to 
distinguish between these two models. Regardless, either process results in the existence 
of parasites which retain the expression of LPG and potentially other ‘early’ virulence 
factors. The retention of these virulence factors may have important effects on the 
infected hosts. LPG has demonstrated roles in parasite survival in macrophages and 
neutrophils, protection against complement-mediated lysis, oxidant avoidance, and the 
inhibition of phagolysosomal fusion (7, 8, 12). LPG retention by the parasites may serve 
to prolong the effects of this virulence factor as the parasites transit through cell types of 
‘first contact’. 
What type of parasite could be transferred from DCs to macrophages? 
Invading metacyclic-stage parasites are thought to interact predominantly with cell types 
other than macrophages in vivo, yet by 48 hours after infection most parasites are found 
within macrophages (38). If we assume that all parasites enter macrophages by way of 
DCs, then the parasite phenotype encountered by macrophages would be entirely 
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dependent on the parasite phenotype(s) present at the time of transfer. We evaluated the 
phenotype of parasites within DCs at 24 and 72 hours post-infection, time points book-
ending the time during which parasite transfer from DCs to macrophages likely takes 
place. At 24 hours post infection, almost all parasites are positive for the amastigote 
markers PFR, T17, and T18, yet retain LPG and cell cycle arrest. By 72 hours after 
infection roughly a third of the parasites retain LPG, cell cycle arrest, and potentially 
other ‘metacyclic’ characteristics. Thus, should parasite transfer occur at any time 
between 24 and 72 hours post infection, macrophages would be expected to encounter a 
mix of parasite phenotypes including both LPG- and LPG+ parasites, with the LPG 
potentially exerting effects not just on the DC but also on the macrophage upon 
subsequent transfer. 
In reality, DCs are not the only cell type with which metacyclic-stage L. major interact, 
and the parasites are thus transferred to macrophages from these other cell types as well. 
In order to understand the parasite phenotype(s) that may be transferred from these cells 
to macrophages, the ability of the parasites to differentiate within these cells must be 
determined. Although it may be tempting to assume that the timing of parasite 
differentiation within different host cells may be similar to what is seen by one of the 
three cell types assessed here, our data suggest that amastigogenesis is strongly 
dependent on conditions, and such assumptions may not be correct. Some of the most 
profound differences seen between cell types in terms of parasite differentiation were 
between different sources of macrophages (PEMs versus BMMs). These two types of 
macrophages could differ in several ways that are potentially relevant to the parasite, 
including in their lysosomal pH or contents or the fusogenicity of Leishmania-containing 
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endosomes, with such differences being either positive or negative regulators of 
amastigogenesis. Thus, the ability of L. major to undergo amastigogenesis within other 
host cell types must be addressed experimentally. In fact, our results in DCs appear to 
contrast with what is seen in human peripheral blood-derived neutrophils, in which at 
least some L. major parasites retain the long, highly motile flagella that is characteristic 
of promastigotes up to 42 hours post-infection (39).   
Potential uses of amastigote markers 
In order to address the ability of L. major to differentiate within DCs, we first had 
to develop amastigote markers, as such tools are limited with Leishmania in general and 
L. major in particular. As the induction of some of the markers (PFR loss and induction 
of T17 and T18 antigens) appear to be ordered, these markers can be used to determine 
the extent to which a parasite has undergone differentiation, with a parasite that is 
positive for all markers being considered fully differentiated. These markers potentially 
have numerous applications in addition to those for which they were used here. Such uses 
might include the evaluation of putative L. major axenic amastigote lines, with the goal 
of finding conditions in which parasites are “positive” for all amastigote markers. In 
addition, these markers could be used to identify environmental signals that positively or 
negatively affect amastigogenesis in vitro, as a higher percentage of parasites would be 
expected to be positive for the amastigote markers as differentiation conditions improve. 
Ultimately, the identification of amastigote markers lays the groundwork for genetic 
studies of amastigogenesis so as to better understand parasite developmental biology. 
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Figure legends 
Figure 1. Characterization of amastigote markers in peritoneal macrophages (PEMs). (A-
D) Comparison of marker expression between metacyclic parasites (left) or parasites 72 
hours post infection of PEMs (i.e. amastigotes, right). (A) Parasite nuclei are detected 
with antisera against L. major histone proteins (green), and PFR is shown in red. (B) 
Parasite histones, red. mAB T17, green. (C) Parasite histones, red. mAB T18, green. (D) 
Endogenous YFP fluorescence (yellow) overlaid onto DIC image. Scale bar represents 5 
µm. (E) Timing of marker induction. The percentage of parasites showing an 
“amastigote-like” phenotype for the various markers is plotted as a function of time after 
infection. N = 3 experiments, error bars represent standard deviation. (F) Summary of the 
data in (E) showing the relative timing of amastigote marker induction in PEMs. 
Figure 2. Parasites within bone marrow-derived macrophages (BMMs) and dendritic 
cells (DCs) induce PFR, T17, T18, and YFP markers similarly to in PEMs. For all 
graphs, PEM data is represented with black diamonds, BMM data is represented with 
grey squares, and DC data is represented with open triangles. The data shown is the 
average of three experiments, and error bars represent the standard deviation. (A) PFR 
loss. (B) Induction of T18 reactivity. (C) Induction of YFP fluorescence. (D) Induction of 
T18 reactivity. Data shown is the mean of three independent experiments, error bars 
represent standard deviation. (E) BrdU-incorporation by parasites in PEMs, BMMs, and 
DCs. Infected host cells were cultured in media containing BrdU for 24 or 72 hours after 
infection.  Black bars, PEMs. Grey bars, BMMs. White bars, DCs. ** denotes P < 0.05 
by Student’s t-test. 
 61
Figure 3. The percentage of parasites within BMM showing an “amastigote-like” 
phenotype for the various markers is plotted as a function of time after infection. N = 3 
experiments, error bars show standard deviation. 
Figure 4. The percentage of parasites within DCs showing an “amastigote-like” 
phenotype for the various markers is plotted as a function of time after infection. N = 3 
experiments, error bars show standard deviation. 
Figure 5. Loss of LPG expression following infection of PEMs, BMMs, and DCs. (A) 
Anti-LPG fluorescence intensity on a per-parasite basis. Anti-LPG intensity of WT 
metacyclic-stage parasites as well as at various time points after infection of PEMs was 
measured as described in Methods. As a negative control, the anti-LPG intensity of L. 
major lpg1- (open circles) was measured 0.3 hr after infection of PEMs. The grey line 
shows the mean anti-LPG intensity of “LPG-negative” WT parasites as determined by the 
qualitative assay plus two standard deviations, and any parasite with anti-LPG values 
below that line would be considered LPG-negative. Data shown is pooled from at least 
two independent experiments. Black bars represent geometric mean of the data for each 
sample. (B) Representative images comparing the LPG-positivity of purified metacyclics 
and parasites within PEMs, DCs, and BMMs at 72 hours post-infection. Parasite nuclei 
are shown in green, LPG is shown in red. Scale bar represents 5 µm. (C) Percent of 
parasites within the three host cell types that are LPG+ as determined by the qualitative 
assay. PEM data is represented with black diamonds, BMM data is represented with grey 
squares, and DC data is represented with open triangles. N = 3 experiments, error bars 
show standard deviation. (D) Quantitation of LPG on the surface of parasites within 
PEMs, BMMs, and DCs at 24 and 72 hours post infection. For comparison, anti-LPG 
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intensity data for metacyclic-stage parasites is also shown (open circles). The grey line 
shows the cut-off for LPG-positivity. Data shown is pooled from three independent 
experiments. Black bars represent geometric mean of the data for each sample, and P 
values were calculated by a Student’s t-test. 
Figure 6. LPG-retaining parasites within DCs 72 hours post-infection have not undergone 
DNA synthesis. Parasites were cultured in the presence of thymadine analogue (EdU) for 
72 hours following infection of DCs or PEMs. Cells were stained to detect EdU-
incorporation (green), LPG (red) and parasite nuclei (blue). (A) Representative image of 
parasites within DCs stained as above. Scale bar represents 5 µm. (B) Percent of parasites 
within DCs 72 hours post-infection (white bars) or PEMs 24 hours post-infection (grey 
bars) that are positive for EdU-incorporation. Data shown include the percent of total 
parasites that are EdU+, as well as the EdU-positivity of parasites that are either LPG-
negative or LPG-positive. In DCs at 72 hours post-infection, almost all EdU+ parasites 
are LPG-negative. This is not the case in PEMs 24 hours post-infection, in which a 
similar percentage of parasites within the LPG+ and LPG-negative pools are EdU+. N = 2 
experiments. * denotes statistical significance as determined by a χ2 test described in the 
text. 
Supplemental figure S1. Loss of arabinose-capped “metacyclic” LPG by parasites within 
PEMs. PEMs were infected with L. major and harvested 2, 24, and 72 hours after 
infection. (Top) Ara-capped LPG is detected with mAB 3F12 (green), and parasite 
histones are shown in red. Scale bar represents 5 µm. (Bottom) Percent of parasites that 
were 3F12+ at indicated time points.  
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Abstract  
Following Leishmania major infection, small numbers of parasites persist indefinitely in 
the host in the absence of pathology. Persistent parasites play important roles in 
concomitant immunity and act as reservoirs for transmission and/or reactivation. We 
sought to examine the replication and localization of persistent L. major in mice. We used 
an in vivo BrdU-labeling assay to show that persistent parasites replicate, albeit ~50% as 
much as acute-phase parasites resulting from the existence of a poorly-replicating sub-
population of parasites unique to persistent infections. Persistent parasite replication 
occurs within macrophages and dendritic cells, ~80% of which synthesized high levels of 
iNOS protein, an enzyme implicated in parasite killing. However, the parasites within 
iNOS+ cells appeared morphologically normal and showed comparable BrdU labeling to 
parasites within iNOS- cells suggesting at least transient survival within iNOS+ cells. 
Since parasitemia remains roughly constant over time, persistent parasite replication 
implies that parasites must also be destroyed. These data shed new light on the persistent 
parasite paradigm, invoking a ‘stem immunogen’ model for concomitant immunity in 
which a generally quiescent reservoir periodically undergoes replication, thus 
maintaining itself while targeting many progeny parasites for destruction within 
professional antigen presenting cells and consequent maintenance of immunity. 
Attenuated lpg2- L. major, a proposed model of WT persistence capable of vaccinating 
susceptible BALB/c mice against virulent challenge, closely resembled persistent WT in 
most respects (e.g. replication and localization within iNOS-expressing phagocytes), but 
differed in its association with host arginase I expression in C57BL/6, but not BALB/c, 
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mice. As lpg2- fails to vaccinate C57BL/6 mice, elevated arginase I expression may be a 
negative correlate of anti-Leishmania immunity. 
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Introduction 
As long-term infection of a host can increase a pathogen’s chances of transmission, an 
array of viral, bacterial, and eukaryotic pathogens have evolved the ability to prolong 
their relationship with their hosts. A subset of pathogens, including Mycobacterium 
tuberculosis, Toxoplasma gondii, and Leishmania major remain indefinitely within their 
hosts in small numbers without causing obvious illness: a condition which we refer to as 
a “persistent” infection. Despite the absence of overt pathology, such persistent infections 
are of great medical importance as they serve as reservoirs for transmission, reactivate to 
cause disease (1), or protect against subsequent infections either by their own species or 
by different pathogens (2), a process known as concomitant immunity.  
Persistence is a significant but under-studied aspect of the biology of parasites of the 
genus Leishmania, which are the causative agents of leishmaniasis. These parasites are 
transmitted as metacyclic-stage promastigotes to humans by the bite of an infected sand 
fly. They are then engulfed by phagocytes such as macrophages, where they differentiate 
into the amastigote stage and begin to replicate. In the case of Leishmania major, this 
may produce an ulcerating skin lesion. In most human cases, as well as in experimental 
infections of “resistant” mouse strains, the infection is eventually controlled by a Th1 
type immune response, an important component of which is the induction of iNOS. It is 
generally thought that iNOS-derived nitric oxide (NO) is responsible for killing 
intracellular L. major, since iNOS knock-out mice fail to control infection (3, 4). 
Following the development of this protective response, the number of parasites in 
infected tissue declines dramatically, the lesion heals, and the host becomes immune to 
subsequent L. major infection. However, a small, roughly constant population of viable 
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parasites remains at the site of infection and in the lymph node draining that site for the 
rest of the host’s life (5).  
These persistent parasites are important for several reasons. First, despite their limited 
numbers (~1000), persistent parasites can still be transmitted to sand fly vectors, and as 
such, are a reservoir for the pathogen (6, 7). Second, they pose a substantial risk to 
infected people in the event of immunosuppression, as the persistent parasites can 
“reactivate” leading to severe disease (8). Finally, they may be beneficial to hosts with 
intact immune systems, as they help maintain protective immunity against subsequent 
Leishmania infections (9). Indeed, healed Leishmania infections are the gold-standard in 
anti-Leishmania immunity, and to date no other vaccination approaches have been 
successful in humans (10). Importantly, treatment of persistently infected mice to achieve 
a sterile cure renders those mice susceptible to new infections (11), suggesting that the 
persistent parasites are actively contributing in some way towards their host’s anti-
Leishmania immunity.  
Because of the strong protective immunity conferred by persistent parasites, an attenuated 
parasite line that could persist indefinitely without causing pathology would be a 
promising candidate for development into a vaccine against leishmaniasis (12). Several 
mutant lines of L. major, (including parasites lacking fructose-1,6-bisphosphatase or the 
nucleotide sugar transporter LPG2) have these properties (13). Of these, lpg2- (which 
lacks a GDP-mannose transporter required for the synthesis of parasite virulence factors 
such as phosphoglycans), can vaccinate susceptible mice against virulent challenge (14). 
In fact, because the number of viable lpg2- in an infected mouse is comparable to that of 
WT persistent parasites, lpg2- has been proposed as a model for L. major persistence. 
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One advantage of this model would be that it would allow the generation of a persistent 
infection only a few weeks after infection with lpg2-, as opposed to months following 
infection with WT (12). 
Considerable evidence suggests that the host’s immune response is important to 
simultaneously prevent reactivation and clearance of persistent parasites. For instance, 
treatment of persistently infected mice with immunosuppressive drugs, iNOS inhibitors, 
or the blockade of interferon-γ signaling rapidly results in increased parasite numbers and 
the reappearance of disease symptoms (4). In contrast, depletion of CD4+CD25+ 
regulatory T cells or the blockade of IL-10 signaling both result in sterile cure in mice 
(11, 15). It remains unknown, however, how persistent parasites modulate the host’s 
immunostimulatory and immunosuppressive responses, or what role persistent parasites 
(or attenuated lines such as lpg2-) have in maintaining protective immunity. In addition to 
immunological studies, studies of persistent parasites themselves are crucial to help us 
address these questions. 
As the number of persistent parasites is roughly constant, we sought to determine if the 
parasites at this stage of the infection replicate or if they are quiescent. To this end, we 
developed a BrdU-incorporation assay and used it to show that acute-phase levels of 
replication was taking place by a sub-population of parasites, while another sub-
population replicated poorly if at all. Taken together, persistent parasites replicate about 
half as much as acute-phase parasites, in which a poorly-replicating sub-population is not 
detected. We found that parasite replication takes place within macrophages and dendritic 
cells in both sites of persistence (the footpad infection inoculation site and the draining 
lymph node). Other cell types, including ER-TR7+ reticular fibroblasts, harbored 10% or 
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less of persistent parasites. Constant parasite numbers despite constant replication implies 
that parasite killing is also taking place. We hypothesized that iNOS-expressing cells 
were the sites of parasite killing and found that ~70% of persistent parasites were within 
such cells. Although the parasites observed within these cells appeared to be healthy and 
replicating, we presume that at least some of the parasites within these cells are killed. 
Continual parasite destruction and repopulation suggest a model by which persistent L. 
major maintain protective immunity, namely by continual presentation of antigens from 
killed parasites. This paradigm of constant immune stimulation could also explain the 
concomitant immunity generated by other pathogens including herpesviruses and 
Toxoplasma. We also assessed the replication and localization of lpg2- parasites. For 
most parameters tested, WT persistent parasites and lpg2- were indistinguishable, further 
supporting the use of lpg2- as a model of WT persistence. However, we found small 
differences in the phenotype of the host cells infected by lpg2- and persistent WT, one of 
which (an increased association within host arginase 1 expression) negatively correlates 
with the ability of lpg2- to vaccinate different strains of mice.  
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Materials and Methods 
Parasite strains and culture 
For most experiments, L. major strains LV39c5 (Rho/SU/59/P),  Friedlin V1 
(MHOM/IL/80/Friedlin),  and lpg2- L. major (Δlpg2::HYG/ Δlpg2::HYG) (12) were 
grown at 26OC in M199 M199 medium (US Biologicals) supplemented with 40 mM 4-
(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) pH 7.4, 50 μM adenosine, 
1 μg ml−1 biotin, 5 μg ml−1 hemin, 2 μg ml−1 biopterin and 10% (v/v) heat-inactivated 
fetal calf serum (16). “Slow-growing” promastigote cultures were grown in RPMI 1640 + 
L-glutamine (Invitrogen) supplemented with 37 mM HEPES pH 7.4, 47 μM adenosine, 
.93 μg ml−1 biotin, 4.7 μg ml−1 hemin, 1.9 μg ml−1 biopterin and 0.9% (v/v) heat-
inactivated fetal calf serum(17). The WT LV39c5 parasites used here expressed GFP 
from the ribosomal locus (SSU::IR1SAT-GFP) and were generated by transfecting SwaI-
cut plasmid B3538 into WT LV39c5 as described (16) and selecting for resistance to 100 
µM nourseothricin and bright green fluorescence. The clone used in this study exhibited 
virulence similar to WT in BALB/c mice (data not shown). Parasites deficient in the 
arginase gene arg- (Δarg::HYG/Δarg::PAC) (18) were cultured in the above media 
supplemented with 50 mM putrescine. Infective metacyclic-stage parasites were 
recovered using the density gradient centrifugation method (19). Propidium iodide 
staining of promastigotes was performed as described (20). 
Mouse infections  
Female C57Bl/6J mice (6-10 weeks old; Jackson Labs) were injected subcutaneously in 
the left hind footpad with either 105 metacyclic WT or 106 metacyclic lpg2- parasites. 
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Following infection with WT parasites, the mice developed lesions that resolved, as 
determined by the absence of footpad swelling relative to the uninfected foot, ~4 months 
after infection.  For the purposes of this study, “persistent” infections were defined as any 
time >1 month following the resolution of footpad swelling. Most studies with lpg2- were 
performed between 1-2 months following infection. Where indicated, some studies with 
lpg2- were performed 5 months after infection. Because lpg2- parasites can revert to 
amastigote virulence (21), it was important to eliminate possible revertants from our 
analysis. To do this, we did not include data from lpg2- -infected mice in which we found 
> 150 parasites in a single section. We chose this cutoff because we calculate that such a 
mouse would likely have ~10000 parasites in the footpad (based on the fact that a normal 
footpad can yield ~60 sections and our observation that the number of parasites within a 
section remains roughly constant within one mouse.) 
Antibodies used 
L. major nuclei were detected with a pool of rabbit antibodies raised against L. major 
histones H2A, H2Avariant, H2B, H3, and H4 (pooled at a ratio of 3:2:3:3:1 by titer) (Wong 
and Beverley, in preparation). For some experiments, this pool was used at a dilution of 
1:750. For others, this pool of antibodies was directly conjugated to Alexafluor488 
monoclonal antibody labeling kit according to the manufacture’s protocol (Invitrogen) 
and the directly conjugated antibody used at a final concentration of 0.15 mg ml−1. GFP 
was detected with a chicken anti-GFP antibody (AbCam) at a final concentration of 0.02 
mg ml−1. F4/80 was detected with a rat monoclonal antibody (clone A3-1, AbD Serotec) 
diluted to 1:250. CD11c was detected with a hamster monoclonal antibody (clone N418, 
eBioscience) diluted to 1:250. ER-TR7 was detected with a rat monoclonal antibody 
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(BMA Biomedicals) used at a final concentration of 0.01 mg ml−1. iNOS was detected 
with a rabbit anti-iNOS (BD Transduction Labs) used at 1 μg ml−1. Relmα was detected 
with a rabbit polyclonal antibody (Abcam) used at 0.8 μg ml−1. BrdU was detected with a 
rat monoclonal antibody (Abcam) used at 10 μg ml−1. Goat anti-Arg1 (Santa Cruz) and 
goat anti-Arg2 (Santa Cruz) were used at 2 μg ml−1. Rat anti-LY-6C mAb (clone RB6-
8C5; kindly provided by L. D. Sibley) was used at a 1:250 dilution. Rabbit anti-
Leishmania arginase (kindly provided by B. Ullman) was used at a 1:1000 dilution. The 
following antisera were screened for reactivity to nitrotyrosine in interferon-γ/LPS 
stimulated macrophages: rabbit anti-nitrotyrosine (Santa Cruz Biotechnology, sc-55256; 
Millipore, #06-284; Abcam, ab50185), mouse anti-nitrotyrosine (Santa Cruz 
Biotechnology, sc-32757), and rat anti-nitrotyrosine (Abcam, ab6479)) 
The following fluorescent secondary antibodies were used: Alexafluor555 goat anti-
rabbit, Alexafluor633 goat anti-rabbit, Alexafluor488 goat anti-rat, Alexafluor555 goat 
anti-rat, Alexafluor633 goat anti-rat, Alexafluor568 goat anti-hamster, Alexafluor488 
goat anti-chicken, Alexaflour555 donkey anti-goat, and Alexafluor647 donkey anti-rabbit 
(Invitrogen, all used at 2 μg ml−1 concentrations).  
Tissue preparation and histological staining 
After euthanasia, infected draining popliteal lymph nodes or feet were harvested. The 
infected tissue was then fixed for 1 h at room temperature in 4% (w/v) paraformaldehyde 
in phosphate-buffered saline (PBS). After fixation, tissues were incubated at 4OC for in 
10%, 20%, and then 30% (w/v) sucrose in PBS. After an overnight incubation in 30% 
 81  
sucrose, the tissues were embedded in O.C.T. compound (Ted Pella, Inc.), cut into 6 µm 
thick sections using a cryostat, and mounted onto microscope slides.  
Unless otherwise indicated, tissue sections were stained as follows. Slides were washed 
in PBS, and tissue were then blocked and permeabolized in PBS containing 5% (v/v) 
normal goat sera (Vector labs) and 0.1% (v/v) Triton-X-100 for 30 min. The sections 
were then stained with various combinations of primary antibodies (as described in the 
text) for 1 h. Unbound antibody was then washed off in PBS and primary antibodies were 
detected with combinations of fluorescent secondary antibodies (as described in the text) 
for 40 min, followed by a second wash in PBS. For some experiments, we needed to 
simultaneously stain tissue sections with different antibodies that were both generated in 
rabbits. To do this, the tissue was stained with an unlabeled rabbit primary antibody and a 
fluorescently-labeled secondary antibody as described above. Next, the tissue was 
blocked for 30 min with a buffer containing 5% (v/v) normal rabbit sera (Sigma Aldrich), 
and then the second fluorescently conjugated primary antibody was used.  
For TUNEL staining of the tissue sections, after all primary and secondary antibody 
staining was finished, the sections were stained with the In Situ Cell Death Detection Kit, 
TMR Red (Roche), according to the manufacturer’s protocol. All sections were mounted 
in ProLong Gold reagent (Invitrogen).  
BrdU staining and in vitro experiments 
For all BrdU experiments, paraformaldehyde-fixed samples were permeabilized with 
0.1% (v/v) Triton-X-100 in PBS for 15 min, washed in distilled water, and then 
immersed in 2 M HCl for 40 min to denature the DNA. After extensive washing with 
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PBS, the samples were incubated in a blocking buffer containing PBS and 5% (v/v) 
normal goat sera and 0.1% (v/v) Triton-X-100, and were then stained as described in the 
text in the methods above. All BrdU stains used a 2 h incubation with the anti-BrdU 
antibody. 
To test BrdU in promastigotes in culture, either log- or stationary-phase L. major 
promastigotes were cultured in M199 media that contained 0.1 mM BrdU (Sigma) for the 
indicated time, after which they were fixed in 4% (w/v) paraformaldehyde in PBS for 10 
min and stained as described above. To test BrdU in infected macrophages in vitro, 
starch-elicited peritoneal macrophages (PEMs) were harvested and infected as described 
with stationary-phase parasites (22). Two hours after parasites were added, the 
macrophages were washed to remove extracellular parasites and placed in media 
containing 0.1 mM BrdU. The infected macrophages were maintained in BrdU-
containing media for the remainder of the five-day experiment. At two hours, 1 day, 2 
days, and 5 days post-infection, samples were fixed and stained as described above.  
BrdU incorporation assay in vivo 
Several different methods were attempted to administer BrdU to the infected mice. In the 
preferred method, infected mice were injected every 3 h hours for 18 h with 200 µl of 
PBS containing 4 mg ml-1 BrdU into the peritoneal cavity and 50 µl of this solution 
directly into the infected footpad, yielding a total dose of 6 mg BrdU. We also tried 
administering BrdU in the drinking water (1 mg ml-1), via infusion using osmotic pumps 
(Alzet #2001D, 7.2 mg total dose), and single intraperitoneal injections of 200 µl of PBS 
containing 4 mg ml-1 BrdU. 24 h after the first dose, the mice were euthanized and 
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footpad tissue prepared and stained as described above. Volocity image analysis software 
(Improvision) was used to assist counting. 
Generation of alternatively activated macrophages 
PEMs were harvested and plated on glass coverslips. 24 h after isolation, the media was 
replaced with fresh media containing 100 U ml-1 each of recombinant IL-4 (BD 
Pharmingen) and IL-13 (BD Pharmingen) for 48 hours. 
Comparison of iNOS staining intensity  
PEMs were isolated and allowed to attach to glass coverslips. 24 h after isolation, the 
media was replaced with fresh media containing 100 U ml-1 recombinant interferon-γ 
(Chemicon) and 100 ng ml-1 LPS (Sigma). 24 h later, the cells were fixed in 4% (v/v) 
paraformaldehyde and stained in parallel with footpad tissue sections from lpg2- -
infected mice with antibodies against L. major histones and iNOS, and nuclei were 
stained with TOPRO-3 (Invitrogen). To determine the fluorescence intensity of iNOS per 
cross-sectional area, the outline of each cell from a confocal stack was traced in Volocity 
software (Improvision) and the sum intensity of all “red” pixels (iNOS) in the selected 
area was divided by the total number of pixels in that area, yielding a mean pixel 
intensity for the cross section.  
Comparison of arginase staining intensity between persistent parasites and 
promastigotes 
Footpad tissue sections infected with persistent WT or log-phase WT promastigotes were 
labeled to detect parasite arginase with a rabbit anti-Leishmania arginase antibody (a gift 
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from B. Ullman, diluted to 1:1000) and parasite histones (with the fluorescently-
conjugated anti-histone antibody). Confocal images were acquired using identical 
settings, and then Volocity image analysis software was used to determine the total 
arginase fluorescence intensity on a per-cell basis. To do this, confocal stacks were 
compressed into a single plane, and then the total arginase fluorescence intensity was 
determined within a 2.28 µm radius circle centered on parasite nuclei. 
Macrophage infections 
PEMs were harvested and plated on glass coverslips in 24 well dishes. The following 
day, some cells were stimulated with 100 U ml-1 recombinant interferon-γ (Chemicon) 
and 100 ng ml-1 LPS (Sigma) with or without the iNOS-inhibitor L-NIL (Cayman 
Chemical) at a concentration of 10 µM. Four hours later, metacyclic stage WT L. major 
strain Friedlin V1 (MHOM/IL/80/Friedlin) that had been opsonized in C5-deficient 
mouse sera were added to the wells with a parasite to PEM ratio of ~10:1. Two hours 
later, extracellular parasites were removed by extensive washing, and some coverslips 
were removed and stained with the DNA stain Hoechst to determine initial parasite titers. 
24 hours after infection, nitrite production was determined by the Greiss assay (Sigma) 
and samples were removed to determine parasite titers. The remaining samples were left 
alone until 72 hours after infection, at which time some samples were removed to 
determine parasite titers. Media containing various combinations of interferon-γ + LPS 
and L-NIL was added at this time point. At 96 hours after infection, nitrite production 
was determined by the Greiss assay, and all samples were stained to detect parasite nuclei 
and DNA. For these experiments, ‘percent survival’ is defined as the ratio of the number 
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of parasites per 100 PEMs at either 24 or 94 hours after infection with the number of 
parasites per 100 PEMs 24 hours earlier.  
Microscopy 
All microscopy of was performed on a Zeiss 510 META confocal laser scanning 
microscope. Cutoffs for saturation and background levels were adjusted with Photoshop 
software (Adobe).  
Statistics 
Throughout the manuscript, data are presented as the geometric mean ± the standard 
deviation. P values are calculated by the Student’s t-test method.  
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Results 
Development of a BrdU incorporation assay for Leishmania 
Preliminary studies of the L. major cell cycle suggest that the parasites extend the 
duration of G1 phase, but not S- or G2 phase, under conditions of slow growth in vitro 
(Supplementary figure S1). This suggests that a  BrdU-incorporation assay (23) would 
allow us to determine if persistent parasites replicate in their hosts and, if so, to compare 
the doubling time of persistent parasites with that of acute-phase parasites. To develop 
this assay, we first examined parasites growing in logarithmic phase in vitro, labeled with 
0.1 mM BrdU for various periods followed by fixation and staining with a pool of 
antibodies specific to L. major histone proteins to label parasite nuclei and anti-BrdU 
antisera (24). As expected, BrdU was incorporated into both the kinetoplast 
(mitochondrial) DNA network and the nucleus. Under conditions where parasites 
replicated with a doubling time of approximately 8 hr, the percent of BrdU+ cells rose 
from 0 to 90% over a period of 9 hr (Figure 1A). Other studies employing longer labeling 
times failed to increase the percentage to higher values, suggesting that this is the 
technical limit of this experimental protocol. As expected, increasing parasite doubling 
time results in a lower fraction of BrdU+ parasites (Supplementary figure S1) and 
addition of BrdU for 12 hr to cultures that had been in stationary phase for 24 hours 
yielded no BrdU+ cells (data not shown). Importantly, culture of L. major-infected 
macrophages in vitro in the presence of BrdU for 72 hr resulted in up to 90% BrdU-
labeling of intracellularly replicating amastigotes, indicating that BrdU can enter the 
phagolysosome.  
 87  
We next tested the ability of BrdU to label replicating parasites in acute mouse infections 
(2-3 weeks post-infection). We tried several different methods to deliver BrdU to the 
mice including in the drinking water, by intraperitoneal injection, through subcutaneous 
infusion from surgically implanted osmotic pumps, and via injection of BrdU into the 
peritoneum combined with direct injection of BrdU into the infected footpad. Mice were 
sacrificed 24 hr after the beginning of the dosing period and the strategy that yielded the 
highest percentage of BrdU+ parasite nuclei was determined.   
Although all of the above strategies resulted in BrdU+ host cell nuclei within our acutely-
infected tissue sections, BrdU+ parasites were only detected in mice that received the 
combined intraperitoneal and subcutaneous footpad BrdU injections. We found that the 
percentage of parasites that labeled in a 24 h period increased linearly with the number of 
doses (Figure 1B). We adopted a dosing regimen of 6 doses given every 3 h as a 
‘standard’ protocol as it presented the maximum dosing schedule tolerable to both the 
mouse and experimenter. Assuming a 24 hr labeling period and a parasite doubling time 
of 60 h (as determined by the use of luciferase-expressing parasites; Hickerson et al, 
unpublished data), we calculate that 40% of acute-phase parasites should be BrdU+. 
Using the above protocol, 44 ± 6% of acute-phase L. major were BrdU+ 24 h after the 
first dose of BrdU, a value which is consistent with our calculations and which we use as 
representative of “maximal” replication. Throughout the remainder of this manuscript, we 
will use the following nomenclature to summarize our summary statistics: N = # of 
experiments (E) / total # of mice (M) / total # of parasites (P). Thus, for the experiment 
described above, N = 2E / 5M / 5289P.  
Persistent parasites replicate in vivo 
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We then tested whether persistent L. major incorporate BrdU into their DNA. Here, we 
define the asymptotic “persistent” phase as >1 month following the resolution of footpad 
swelling at the inoculation site. When persistently infected mice were treated with BrdU 
as described above, 19 ± 6% of persistent parasites had BrdU+ nuclei (N = 2E / 6M / 
578P; Figure 1C and D). These data establish for the first time that persistent parasites 
replicate in vivo.  
As a second sign of parasite replication, we developed an indirect assay based on the 
distribution of parasites within the tissue. This assay is based on the assumption that in 
the persistently-infected state, host cells are initially infected by a single parasite, as the 
low number of parasites present in the tissue makes multiple independent infections of 
the same host cell unlikely.  Thus, host cells containing two or more parasites can be 
viewed as sites of intracellular replication. Using this indirect assay, we regularly found 
instances in which host cells contained between 2-20 L. major cells, which we refer to as 
“parasite clusters”. Roughly half of all infected cells contain 2 or more parasites, and 
~80% of all parasites are found in “clusters” (N = 3E/8M/888P; 386 infected cells; Figure 
2A and B).  
Interestingly, the percentage of BrdU+ parasites was about 50% as much as that of acute-
phase parasites (P < 0.0001 by Student’s t-test). Assuming that persistent parasites 
replicate as a homogeneous population, the percent labeling observed here suggests about 
2-fold slower replication, or a doubling time of ~120 hr. Alternatively, these data would 
fit a model where about ½ of the parasites replicate at rates comparable to exponentially 
growing parasites (44% labeling), while the others are either dead or in some kind of 
arrest. We sought to differentiate between these models by plotting the percent of parasite 
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clusters as a function of the percent BrdU-labeling within those clusters. Assuming that 
the parasites are replicating homogeneously, we would anticipate a distribution of percent 
labeling centered at the mean. Acute-phase parasites fit this model, with 61% of all 
clusters showing between 21% and 70% labeling. In contrast, persistent parasites do not 
show a single distribution centered at 19% labeling, but rather appear to have two peaks 
representative of two different types of clusters (Figure 2C). The first type, which 
accounts for ~60% of the total clusters, is not labeled with BrdU during the duration of 
the experiment. The other population had a mean labeling frequency of 57 ± 21% (N = 
2E/5M/170P/50 clusters). This second population resemble acute phase parasites (mean 
labeling frequency of 46 ± 29%; N = 2E/5M/585P/77 clusters). While this analysis 
strongly suggests the existence of a poorly-replicating sub-population, it excludes data 
from parasites not in ‘clusters’, which account for ~20% of all persistent parasites. We 
thus re-analyzed the above data, plotting percent BrdU labeling as a function of the 
number of parasites per infected cell. Assuming homogeneous parasite replication, 
roughly 44% of acute-phase and 19% of persistent parasites should be BrdU+, regardless 
of the number of parasites per host cell. The data from acute-phase parasites very closely 
matches this prediction, with 40-50% BrdU-labeling independent of the number of 
intracellular parasites (N = 2E/5M/976P/176 infected cells). However, once again the 
persistent parasite data do not fit a homogeneous replication model. ~12% of the parasites 
in host cells containing 1 to 3 parasites are BrdU+, while ~46% of the parasites within 
‘clusters’ containing 4 or more parasites are BrdU+ (Figure 2D; N = 2E/6M/379P/167 
infected cells). These results suggest that a population of host cells contain persistent 
parasites that replicate similarly to acute phase parasites, whereas another population of 
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host cells contains parasites that replicate poorly. This second population is not apparent 
in acutely infected mice.  
Persistent parasites predominantly reside in macrophages and dendritic cells   
We also sought to determine the localization of persistent parasites. Footpad and lymph 
node sections were stained to detect L. major nuclei and host cell-type specific markers. 
At least three cell types have been proposed as hosts for persistent parasites: fibroblasts, 
macrophages, and dendritic cells (25-27). Here, we define fibroblasts as cells that are 
recognized by anti-ER-TR7 antisera, dendritic cells (DCs) as cells expressing CD11c 
(either F4/80+ or F4/80-), and macrophages as F4/80-positive, CD11c-negative cells. For 
this and other experiments, confocal microscopy allowed us to ensure that persistent 
parasites were actually ‘within’ the host cells, as we could visualize the host cell plasma 
membrane or cytoplasm (depending on the antibody used) in the X, Y, and Z planes. 
Only 2 ± 3% of persistent parasites in footpad tissue and 10 ± 7% of persistent parasites 
in lymph nodes were within are within ER-TR7+ host cells (footpad N = 3E / 6M / 528P; 
lymph node N = 2E / 4M / 191P), despite the presence of numerous ER-TR7+ cells in 
each field from both sites. In contrast, 80 ± 6% of footpad persistent parasites and 87 ± 
12% of lymph node persistent parasites were found within F4/80+ cells in tissue (footpad 
N = 3E / 8M / 983P; lymph node N = 2E / 4M / 208P). 13 ± 2% of persistent footpad 
parasites and 61 ± 19% of lymph node parasites were within CD11c+ cells (footpad N = 
3E / 8M / 1074P; lymph node N = 2E / 4M / 208P; Figure 3A and B). By dual-staining 
sections to simultaneously detect L. major histone proteins, CD11c, and F4/80, we found 
that 78 ± 9% of footpad persistent parasites were within F4/80+CD11c- macrophages, and 
16 ± 6% were within F4/80+CD11c+ DCs in footpad tissue (N = 2E / 4M / 266P). In 
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lymph nodes, 30 ± 18% of persistent parasites were within F4/80+CD11c- cells, and 61 ± 
19% were within F4/80+CD11c+ DCs. Importantly, essentially all footpad persistent 
parasites (97 ± 3% in footpads and 91 ± 5% in lymph nodes) imaged in this experiment 
were labeled with one or both markers, showing that almost all persistent parasites are 
within macrophages and dendritic cells at both sites (with ~10% of lymph node parasites 
in ER-TR7+ fibroblasts) and that a major host cell type was not missed (Figure 3C).  
The distribution of persistent parasites suggests intracellular replication in both 
macrophages and dendritic cells 
We used the “parasite cluster” analysis described above to address where parasite 
replication takes place. Similar to the distribution of total persistent parasites within host 
cell types in footpads, 74 ± 5% of parasite clusters occurred within host cells expressing 
F4/80, while 17 ± 5% were within CD11c+ cells. These data suggest that the intracellular 
replication takes place within both macrophages and dendritic cells as the percentage of 
parasite clusters within F4/80+ cells (which include CD11c+ cells) greatly exceeds the 
percentage of clusters within CD11c+ cells (Table 2). We plotted the percent of infected 
cells expressing CD11c as a function of the number of parasites per cell to determine if 
dendritic cells preferentially harbor the ‘static’ sub-population which tends to be within 
host cells containing <3 parasites but did not see any obvious correlation (Supplementary 
figure 2A; N = 3E/8M/283P/124 infected cells.)  
Macrophages infected with persistent L. major in footpad tissue do not express markers 
of alternative activation.   
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We hypothesized that some F4/80+ cells containing persistent L. major may be 
alternatively activated macrophages and that these cells may provide a favorable 
environment for parasite survival. To test this, we stained footpad sections from 
persistently infected mice to detect parasite histones, F4/80, and RELMα (a marker of 
alternatively activated macrophages) (28, 29). As above, the majority of persistent L. 
major were within F4/80+ cells (96 ± 2%), but none of these infected cells expressed 
RELMα (N = 2E/3M/284P). Positive controls included the visualizing of F4/80+RELMα+ 
cells elsewhere in the same tissue sections and the ability of the anti-RELMα antibody to 
yield 70-80% positive cells in alternatively activated macrophages obtained by IL-4 and 
IL-13 treatment of peritoneal macrophages (Supplementary figure S1). These data 
suggest that persistent parasites do not favor alternatively activated macrophages as a site 
of replication.  
Most persistent L. major are found within iNOS+ macrophages and dendritic cells 
The finding that persistent parasites replicate suggests that they must also be destroyed, 
or else parasites number would increase. Nitric oxide (NO), generated from L-arginine 
via iNOS, is essential for the control of L. major in vivo, and as such, it has been assumed 
that L. major is killed within iNOS-expressing host cells (3, 4, 30). Thus we asked 
whether some fraction of persistent parasites was found within iNOS+ host cells and 
whether it is within these cells that the parasites are destroyed. 59 ± 15% of persistent 
parasites in footpads were found within iNOS-expressing cells (N = 3 E / 8M / 2535P).  
In addition, 80 ± 19% percent of persistent lymph node parasites are within iNOS+ cells 
(N = 2E / 4M / 477P), in agreement with previously published data (30).  
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Both of the major persistent parasite-harboring host cell types (macrophages and 
dendritic cells) were found to express iNOS when infected with persistent L. major. 10 ± 
6% of total persistent parasites were found within CD11c/iNOS double positive cells 
(Figure 4A; N = 3E / 8M / 1074P). As our instrument can capture at most 3-color images, 
we were unable to simultaneously visualize parasites with F4/80, CD11c, and iNOS. 
However, the fact that the percentage of parasites within F4/80+iNOS+ cells (42 ± 14%; N 
= 3 E / 8M / 983P) is more than 3 times the total fraction of parasites within CD11c+ cells 
argues that many of the F4/80+iNOS+ cells were macrophages (Figure 4B). 
Persistent L. major survive and replicate within iNOS-expressing cells  
We asked next whether the persistent parasites seen in iNOS+ cells showed evidence of 
destruction.  First, we evaluated whether the parasites in iNOS-expressing host cells were 
morphologically intact. The parasites used in these experiments express GFP, allowing 
the parasite cytoplasm within host cells to be clearly delineated using a chicken anti-GFP 
antibody while iNOS expression is simultaneously visualized using a rabbit anti-iNOS 
antibody. In these studies, parasites within iNOS+ host cells were morphologically 
normal and indistinguishable from persistent parasites within iNOS- host cells, suggesting 
that the parasites in iNOS-expressing cells are intact (Figure 4C). In addition to overall 
cellular morphology, the integrity of the parasite’s nuclear genome is a good marker for 
parasite viability (31). Of the 80 parasite nuclei visualized in these experiments with the 
anti-histone antisera, 79 were within iNOS+ cells. However, none of these parasite nuclei 
had TUNEL+ nuclei regardless of their localization within iNOS+ or iNOS- cells (Figure 
4D; N = 2E/3M/80P). In contrast to the result for nuclear DNA integrity, a population (26 
± 15%) of persistent parasites had TUNEL+ kinetoplast DNA. As kinetoplast replication 
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involves the transient formation of double-stranded breaks that are recognized by the 
TUNEL reaction (32), this may be expected of healthy cells.  
To determine if parasite replication was taking place in iNOS+ cells, we determined if 
parasites within iNOS expressing cells incorporate BrdU. We stained tissue sections from 
persistently-infected mice that had been injected with BrdU (as described above) to 
simultaneously detect parasite histones, BrdU, and iNOS. In these sections, 82 ± 10% of 
the parasites were within iNOS+ cells, slightly higher than that seen in other experiments 
(P = 0.03 by the Student’s t-test). 85 ± 13% of the BrdU+ parasites were within iNOS+ 
cells, suggesting that persistent parasite replication does not preferentially occur within 
iNOS- host cells (Figure 4E and Table 1, N = 2E / 3M / 254P)   
To further examine if persistent parasites replicate within iNOS-expressing cells in vivo, 
we used the indirect assay of replication looking for “parasite clusters” within iNOS 
expressing cells and found that 61 ± 9% of persistent parasites “clusters” (Table 1, N = 
3E / 8M / 329 clusters) occurred within cells expressing iNOS. The percent of parasites 
within iNOS+ cells does not obviously correlate with the number of parasites per infected 
cells (Supplementary figure 2B; N = 3E/8M/305P/137 infected cells), suggesting that 
neither the fast-replicating nor poorly-replicating sub-population of parasites are 
preferentially found within these cells. Taken together, these data show that infected 
iNOS-expressing cells may be at least transiently permissive host cells for persistent 
parasites. 
Persistently infected cells express high levels of iNOS 
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One explanation for the apparent survival of persistent parasites within iNOS+ cells might 
be that the level of iNOS expression by persistently infected cells is lower than that of 
cells which generate lethal levels of NO. To test this, we compared the iNOS staining 
intensity between persistently infected iNOS+ cells with that of interferon-γ/LPS-
activated PEMs, which kill L. major in an iNOS-dependent manner (33). Quantitation of 
iNOS staining intensity per cell area showed that in vivo persistently infected host cells 
actually expressed higher relative iNOS levels than did the activated PEMs in vitro 
(Figure 5; 1.6 fold higher average fluorescence intensity; P < 0.001 by Student’s t-test).  
Thus reduced iNOS expression cannot account for the survival of persistent parasites in 
iNOS+ host cells, suggesting that the cells containing persistent parasites in vivo express 
sufficient iNOS to generate leishmanicidal levels of NO. 
Neither host nor parasite arginase is up-regulated in association with infected iNOS-
expressing host cells 
iNOS mediated NO synthesis requires arginine, and depletion of arginine through the 
action of arginase in infected or neighboring cells could serve to limit NO production 
despite high levels of iNOS (34). Mice synthesize two isoforms of arginase which differ 
in their sub-cellular localization: Arg1 which is cytoplasmic, and Arg2, which is 
mitochondrial (35). Parasite infected host cells were visualized using anti-histone antisera 
and scored for iNOS+ and arginase(1 or 2)+; additionally, we scored whether adjacent 
cells (defined as in physical contact with the parasite-infected cell) were arginase+. We 
chose to look at cells ‘adjacent’ to the infected cell because some arginase-expressing 
cells are thought to deplete arginine in their immediate vicinity (36, 37). In these 
experiments 83 ± 14% of persistent parasites were within iNOS expressing cells, 
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however only 3 ± 3% were within cells that simultaneously expressed iNOS and Arg1, 
and only 12 ± 11% of WT persistent parasites within iNOS+ cells were adjacent to an 
Arg1+ host cell (Figure 6A).   Pooling these data we find that 15 ± 14% of persistent 
parasites within iNOS-expressing cells are either within or adjacent to an Arg1+ cell (N = 
3E / 5M / 317P). We did not detect any persistent footpad parasites within iNOS+ cells 
that were also within or adjacent to Arg2+ host cells (N = 2E / 2M / 175P) despite seeing 
regions of intense Arg2 staining elsewhere in the tissue (all of which were > 75 microns 
from parasites) indicative of proper Arg2 reactivity (data not shown).  
While L. major also have an arginase gene, promastigotes do not appear to express 
sufficient arginase to affect NO production by activated macrophages in vitro (18, 38). 
However, persistent parasites may express higher levels of arginase. We stained in 
parallel L. major promastigotes and footpad tissue sections from persistently-infected 
mice to detect parasite histones and parasite arginase and compared their relative arginase 
staining intensity on a per-cell basis (Figure 6B and C). We find that most, if not all, 
persistent parasites express some level of arginase (N = 2E / 2M / 65 P). However, the 
mean relative arginase fluorescence intensity of promastigotes was 2-fold higher than that 
of persistent parasites when differences in background fluorescence are taken into 
account (P = 10-6 by the Student’s t-test), suggesting that L. major do not up-regulate 
arginase during the persistent phase of the infection (Figure 6D).  
Amastigotes are more resistant to NO than metacyclics within activated macrophages in 
vitro 
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Our findings that persistent parasites within iNOS+ host cells appear viable was 
surprising and suggested that persistent parasites may be more tolerant of NO than 
promastigotes. As a surrogate for persistent parasites, we sought to compare the NO 
tolerance of amastigotes with that of metacyclic promastigotes in vitro. As expected, 
metacyclic-stage parasites were rapidly killed in an within peritoneal macrophages 
(PEMs) that had been pre-treated with interferon-γ and LPS, with 10-fold fewer parasites 
surviving 24 hours after infection than parasites added to untreated PEMs (Figure 7A; P 
< 0.05). Treatment of activated PEMs with the specific iNOS inhibitor L-NIL (39) 
reduced the parasite mortality showing that parasite killing is iNOS-dependent (Figure 
7A). In contrast, parasite killing by activated macrophages was greatly reduced when 
metacyclic-stage L. major were allowed to infect PEMs for 72 hours (in which time they 
differentiate into amastigotes and begin to replicate) prior to the addition of interferon-γ 
and LPS. Under these conditions, 94 ± 17% of the parasites remain 24 hours after host 
cell stimulation despite the production of substantial quantities of NO by the stimulated 
macrophages. Relative to unstimulated controls or cells stimulated in the presence of L-
NIL (in which the parasite number continues to increase) there is a 1.5-fold reduction in 
parasite titers in the stimulated PECs (Figure 7B). These data suggest that amastigotes are 
substantially more tolerant of NO than are promastigotes (94% versus 6% survival; P < 
0.001 by the Student’s t-test).  
Attenuated lpg2- L. major resembles WT persistent parasites in most respects 
L. major parasites lacking the LPG2 gene (lpg2-) are a proposed model of Leishmania 
persistence (12). We sought to determine the cell types infected by lpg2- in footpad tissue 
and whether these parasites replicate in vivo. Because lpg2- appears to enter a 
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persistence-like state almost immediately, we performed most experiments 1 month after 
infection (versus 5 or more months post infection with WT parasites). At this time point, 
lpg2- resembled WT persistent parasites for most of the parameters tested above (Table 
2). Among these WT persistent parasites and lpg2- were indistinguishable from each 
other in terms of the percent of parasites labeling with BrdU, the percent of parasites 
within F4/80+ cells, and the percent of parasites found within iNOS+ host cells. Like 
persistent WT parasites, lpg2- parasites were not found within cells labeled with the 
markers ER-TR7, RELMα, nor cells that express high levels of Arg2. In addition lpg2-, 
like WT persistent parasites, replicate within iNOS-expressing cells by both BrdU and 
cluster analysis. 
More lpg2- parasites are within dendritic cells or associated with Arg1+ cells than 
persistent WT 
We found two differences between the phenotype of cells infected with lpg2- versus 
those infected with persistent WT parasites (Table 2). First, the frequency of lpg2- within 
CD11c+ cells was elevated 3-fold relative to WT persistent parasites (46 ± 29%, P < 
0.006; N = 3E / 10M / 1004P). Among the lpg2- -infected mice, there appears to be a 
bimodal distribution of parasites within CD11c+ cells (in one group, <40% of the 
parasites are within CD11c+ cells, while in the other, >60% of the parasites are within 
these cells). Both of these groups were present in all experiments. We also looked to see 
if either group was associated with higher expression of iNOS relative to the other group, 
but found no obvious correlation.  
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There was also a clear difference between WT and lpg2- parasites in terms of their 
association with Arg1. 37 ± 41% of lpg2- parasites were found in iNOS+/Arg1+ host cells 
with another 35 ± 32% found in iNOS+ host cells adjacent to an Arg1+ host cell. In total, 
72 ± 26% of persistent footpad lpg2- parasites were associated with Arg1 expression 
which is roughly 5-fold higher than WT (P = 0.002, N = 3E / 5M / 477P). 
Differences between the cell association of persistent WT and lpg2- parasites are not due 
to the duration of infection 
The observed differences between the two parasite lines could result from differences in 
the duration of infection (e.g. one month for lpg2- versus >5 months for persistent WT). 
Thus, we compared the association of lpg2- parasites one month after infection with that 
of lpg2- 5 months after infection focusing on their association with CD11c and Arg1. 78 
± 13% of lpg2- parasites are within CD11c+ DCs 5 months after infection (Figure 8A; N 
= 2E / 5M / 520P). This is 6-fold higher than what is observed for persistent WT (P < 10-
6) and 1.7-fold higher than lpg2- at one month (P = 0.03). In addition, 85 ± 12% of lpg2- 
parasites within footpad tissue 5 months after infection are either within or directly 
adjacent to a cell expressing Arg1 (Figure 8B; N = 2E / 5M / 901P). Although this was 
indistinguishable from lpg2- at one month post-infection (68 ± 27%), it is 5-fold higher 
than persistent WT (P < 10-3). Taken together, these data suggest that the differences 
observed between persistent WT and lpg2- are not the result of differences in the duration 
of the infection but are more likely due to differences in the interactions between the two 
parasite lines and the host.  
Association with Arg1 negatively correlates with the ability of lpg2- to vaccinate mice 
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Unlike WT persistent parasites, lpg2- does not vaccinate C57BL/6 mice without the use 
of CpG DNA as an adjuvant (40). We asked whether the observed differences between 
lpg2- and persistent WT correlate with the relative inability of lpg2- to vaccinate mice of 
this strain. To address this, we investigated the association of lpg2- parasites and host 
cells expressing these proteins in BALB/c mice, which become highly immune to L. 
major infections following vaccination with lpg2- (14). The percent of lpg2- within 
CD11c+ cells in BALB/c mice is indistinguishable from that of lpg2- in C57BL/6 mice 
(44 ± 21% versus 46 ± 29%; N = 2E / 10M / 745P), and significantly higher than what is 
seen for WT persistent parasites (Figure 8A; P = 0.001). Thus, the presence of lpg2- 
parasites within CD11c+ dendritic cells does not correlate with the ability of the parasite 
to vaccinate its hosts. 
On the other hand, the association of lpg2- with host Arg1 expression does change 
depending on its ability to vaccinate mice. Unlike lpg2- within C57BL/6 mice, in which a 
relatively high percentage of the parasites (72%) are either within or adjacent to an Arg1-
expressing cell, only 16 ± 25% of lpg2- in BALB/c mice is associated with Arg1 (Figure 
8B; P < 0.005; N = 2E / 9M / 1105P), and are thus indistinguishable from WT persistent 
parasites in a C57BL/6 mouse. These data suggest that Arg1 expression may be a 
negative correlate of L. major immunity.   
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Discussion 
Replication and localization of persistent L. major 
In this study, we examined the localization of persistent L. major in the footpad 
inoculation site and the draining lymph node. At both sites, parasites were 
overwhelmingly found within either F4/80+CD11c- macrophages or F4/80+CD11c+ 
dendritic cells with ~10% of lymph node persistent parasites within ER-TR7+ reticular 
fibroblasts. A high percentage of both infected macrophages and dendritic cells expressed 
iNOS in lymph node and footpad tissue. 
Because the number of persistent parasites remains roughly constant over time, it has 
previously been difficult to determine whether these parasites are replicating or not, as 
constant populations could result from either a long-lived, non-replicating form of the 
parasite or continual parasite replication and destruction. Traditional methods for 
determining parasite replication in vivo (such as limiting dilution assays) cannot 
distinguish between these two scenarios. We therefore developed a BrdU-incorporation 
assay to detect parasite replication in vivo. Using this assay, we found for the first time 
that persistent parasites do indeed replicate in footpad tissue.  
Identification of fast-replicating and poorly-replicating subpopulations 
Interestingly, persistent parasites showed about 2-fold less BrdU incorporation than 
acute-phase parasites after a 24 hour labeling period. Further analysis of our data 
identified two populations of host cells. The first population is characterized by a low 
number of intracellular parasites (less than 3) and a low percentage of BrdU-labeling 
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(~12%) while the other population had a larger number of intracellular parasites and 
BrdU-labeling comparable to acute-phase parasites (46%). These data suggests that there 
are either two populations of parasites based on their relative replication or two 
populations of host cells based on their relative ability to permit parasite replication. As 
the poorly-replicating population of parasites tends to be within host cells containing 1-3 
parasites, we looked to see if cells expressing CD11c or iNOS were correlated with 
relatively low intracellular parasite burdens, but we found no obvious association. 
Another question is whether or not the poorly replicating parasites are alive and in some 
sort of stasis or are dead/dying. While current technologies do not allow us to definitively 
answer this question, we favor the model that the poorly replicating parasites are alive 
because we were unable to detect any parasites that were morphologically abnormal or 
that had degraded DNA. Further suggesting that these parasites are alive, parasites killed 
intracellularly are digested by the macrophage and disappear rapidly (31) and therefore 
would be difficult to find.  
Our finding that a large percentage of persistent L. major is in a non-replicating state fits 
in well with data from other organisms which cause life-long asymptomatic persistent 
infections. Herpes viruses, which express only a few select transcripts during latent 
infections (41), are probably the best example of a pathogen that has adopted a strategy of 
quiescence to facilitate persistence. In addition, Toxoplasma gondii persist within their 
host in the poorly replicating bradyzoite stage (42), and a population of persistent 
Mycobacterium tuberculosis are proposed to be in a quiescent ‘persister’ state (43). 
Presumably, quiescence helps these pathogens avoid the immune response and increase 
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their antimicrobial tolerance. Leishmania may be benefited in the same ways, which may 
explain the difficulty of achieving a sterile cure of persistent infections (44).  
With the exception of persistent Leishmania, the quiescent forms of the pathogens listed 
above are known to have distinct gene expression profiles from the actively replicating 
forms (45-47). It is not yet known whether or how the quiescent persistent parasites differ 
from the replicating persistent parasites or if persistent parasites in general differ from 
acute-phase amastigotes. Future studies comparing the gene expression profiles of 
persistent parasites with acute phase parasites, as well as quiescent persistent parasites 
(enriched in small clusters) versus replicating persistent parasites (enriched in large 
clusters) will be crucial to see if Leishmania also has a stage of its life cycle that is 
specifically devoted to persistence.  
Persistent parasites within iNOS-expressing cells appear healthy 
As NO-synthase activity is an essential component of L. major killing by activated 
macrophages in vitro (33) and in the control of experimental leishmaniasis by resistant 
mice (3, 48) we postulated that iNOS-expressing cells were sites of parasite destruction. 
Surprisingly, however, the parasites that we observed within these cells were not 
‘corpses’ but rather were morphologically normal and had intact nuclear genomes as 
determined by TUNEL staining. Furthermore, these parasites appeared to be replicating 
both by the ‘parasite cluster’ criteria and by BrdU-incorporation data. Taken together, 
these data suggest the parasites we observed within iNOS-expressing cells were at least 
transiently viable.  
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Our data therefore raise the question of whether these infected iNOS-expressing cells 
generate lethal amounts of NO. The level of iNOS protein within persistently infected 
cells is comparable to that of interferon-γ/LPS-treated peritoneal macrophages, which 
produce lethal amounts of NO, suggesting that the capacity of persistently infected cells 
to generate NO is not limited by insufficient iNOS expression. Although we cannot 
measure the levels of reactive nitrogen within infected iNOS-expressing cells in vivo, we 
can look at known pathways that may attenuate iNOS activity; one of which being the 
arginase pathway. This pathway could potentially compete with iNOS for its substrate 
(L-arginine), resulting in less nitric oxide production. As mentioned above, very few WT 
persistent parasites within iNOS-expressing cells are associated with elevated levels of 
Arg1 expression and we see no association of persistent parasites with elevated levels of 
Arg2. As such, it is unlikely that either isoform of host arginase attenuates the ability of 
iNOS-expressing cells to generate NO. In addition to Arg1 and Arg2, L. major express 
their own arginase. However, the arginase activity within L. major is extremely low in 
vitro and does not appear to impact the amount of NO produced by classically activated 
macrophages infected with promastigote-stage parasites (18, 38) . Using antibodies 
specific to parasite arginase, we show that persistent parasites (most of which were within 
iNOS-expressing cells) do not increase arginase expression relative to promastigotes, 
suggesting that parasite arginase is not an anti-iNOS defense mechanism. Furthermore, 
preliminary data show that arg- L. major are capable of persistence within resistant mice 
following healing (J. Uzonna, personal communication). Based on these data, it seems 
unlikely that parasite-derived arginase affects the capacity of host cells to generate NO. 
While there may be other mechanisms, such as aggresome formation or iNOS miss-
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localization, by which high levels of iNOS are expressed without the parasites 
experiencing high levels of NO (49-51), we saw no evidence of such mechanisms in our 
samples and, as such, we suspect that at least some if not all iNOS-expressing cells are 
capable of generating large quantities of NO. Survival of persistent parasites within such 
cells would suggest that persistent parasites are more resistant to the ill effects of NO 
than are promastigotes. Indeed, our in vitro studies show that amastigotes are 
substantially more resistant to NO than are promastigotes.  
Comparison of WT persistent and lpg2- identified arginase 1 as a negative correlate of 
immunity 
One of the aims of this work was to compare the candidate vaccine line lpg2- with WT 
persistent parasites: the gold standard in anti-Leishmania vaccines. Previous work has 
shown that lpg2- L. major differs from WT parasites in terms of its ability to survive 
within macrophages in vitro and to cause pathology in vivo. However, it resembles WT 
persistent parasites since it is found in mice in numbers comparable to WT persistent 
parasites (12) and can vaccinate susceptible (BALB/c) mice against virulent challenge 
(14). Here, we found that lpg2- was indistinguishable from WT persistent parasites in 
most respects. Like persistent WT, lpg2- parasites are not found within ER-TR7+ cells 
but do infect macrophages and DCs, some of which express iNOS. In addition, our 
preliminary data also suggests that lpg2- recruits Foxp3+ cells to the site of infection in 
BALB/c mice (data not shown), a phenomenon that is also reported for persistent WT 
parasites (11). Finally, lpg2- and WT persistent parasites are indistinguishable in terms of 
replication, most of which takes place within iNOS expressing cells. Taken together, 
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these data continue to support the use of lpg2- parasites as a model of Leishmania 
persistence. 
However, our work has also demonstrated clear differences between WT persistent 
parasites and lpg2-. In particular, significantly more lpg2- parasites were within DCs and 
are associated with Arg1 expression in the footpads of C57BL/6 mice than is the case 
with WT persistent parasites. We ruled out the possibility that these differences are the 
result of differences in the duration of the infection as the association of lpg2- parasites 
with CD11c and Arg1 in mice infected for more than 5 months more closely resembles 
that of lpg2- at one month post-infection than WT persistent parasites. Instead, these 
differences are likely related to differences in the mouse’s immune response to the two 
parasite lines, and may correlate with the inability of lpg2- to vaccinate resistant 
(C57BL/6) mice without the addition of CpG DNA as an adjuvant (40). Indeed, we found 
that the association of lpg2- and host Arg1 correlate inversely with the ability of lpg2- to 
vaccinate its host, as lpg2- parasites within BALB/c mice (which are protected by 
vaccination with lpg2-) more closely resemble persistent WT than lpg2- in a C57BL/6 
mouse with regards to Arg1 association. Whether the increased association of parasites 
with Arg1 results from or is causative of conditions leading to vaccine failure remains 
unknown. However, Arg1, along with iNOS, can lead to arginine-depleted 
microenvironments which have strong inhibitory effects on both T-cell proliferation and 
function and induce regulatory T-cell differentiation (36, 52). In fact, arginine depletion 
has been shown to impair Leishmania-specific T-cell responses (53). In addition, 
products of Arg1 activity such as urea and polyamines may also have immunosuppressive 
effects (54-56). Thus, the up-regulation of Arg1 in lpg2- -infected C57BL/6 mice 
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provides a viable explanation for why the immunity generated by this attenuated parasite 
line is weak in these mice. 
Models of L. major persistence 
It has long been assumed that persistent L. major required “safe cells” to evade lethal 
nitric oxide that would otherwise result in parasite clearance. Two cell types, ER-TR7+ 
reticular fibroblasts and alternatively activated macrophages have been implicated as 
such “safe cells” as they do not express high levels of iNOS (25, 26). However, as 
mentioned above, the persistent L. major found within iNOS+ cells are apparently healthy 
by all criteria tested. As such, a cell’s capacity to express high levels of iNOS protein 
may not be a good indicator of how “safe” that cell would be for persistent parasites. 
In addition, if the parasites do indeed require safe cells, then such cells should be found at 
all sites of parasite persistence (i.e. the site of inoculation and the lymph node draining 
that site). Although our data is in agreement with the published literature about the 
presence of a population of persistent parasites within ER-TR7+ fibroblasts in lymph 
nodes, we find little, if any, association of persistent L. major with this marker at the site 
of inoculation (the footpad). Instead, we find that the vast majority of the parasites in 
both footpad and lymph node tissue are within macrophages and dendritic cells. Further 
investigation revealed that infected macrophages do not express RELMα, a marker of 
alternative activation, and instead expressed iNOS, a marker of classical activation that is 
repressed in alternatively activated macrophages (29). While these data do not exclude 
the possibility that there is a “safe cell type” that serves as a reservoir for persistent L. 
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major, they demonstrate that neither reticular fibroblasts nor alternatively activated 
macrophages are major reservoir host cell types for parasite persistence.  
Our data suggest an alternative model of L. major persistence (Figure 9). We have shown 
that a population of persistent parasites replicate comparably to acute-phase parasites. 
However, despite substantial replication by these parasites, the parasite number remains 
roughly constant, thus implying that parasite replication is offset by parasite killing. In 
this model, the offspring of replicating parasites infect new host cells where they have 
three potential fates. They may either continue active replication, become ‘static’ or be 
destroyed. How the eventual fate of the parasites is decided is not known and may be 
either stochastic or depend on the phenotype of the host cell infected. 
A stem immunogen model of concomitant immunity 
The constant replication and destruction of persistent Leishmania may help explain the 
concomitant immunity induced by either persistent WT or lpg2- parasites. While 
replicating or static parasites likely have roles in perpetuating the infection, killed 
parasites might be a good source of antigen that could be presented to the immune 
system, maintaining a robust anti-Leishmania response. This assumption is reasonable, as 
antigens from dead parasites can be presented to the immune system whereas live 
parasites have been shown to inhibit antigen presentation by their host cell (57-59). As 
parasite replication and destruction would be a continual process in a persistently infected 
host, such constant boosting would result in the life-long immunity observed in healed 
Leishmania patients. Thus, from the host’s perspective, persistent parasites serve as a 
continually self-renewing vaccine. 
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In some respects, the model we propose here is comparable to stem cell biology (Figure 
9). Like stem cells, persistent L. major are capable of distinct fates: either self-
regeneration or ‘differentiation’ into a cell that has functional consequences which in this 
case is death and immune stimulation. Here, the replicating parasites represent a 
continually self-renewing “stem” with some of the progeny parasites surviving either as 
replicating or quiescent forms. However, many of the progeny parasites become 
‘terminally differentiated’ within antigen presenting cells, which could result in immune 
stimulation. Modulations of the host’s immune response would affect the flux of parasites 
going down one pathway versus the other, resulting in reactivation or sterile cure as 
extremes (4, 11). 
The stem immunogen model relies on the assumption that immune stimulation results 
from the presentation of antigens derived from killed persistent parasites, a point that has 
not been established. In fact, although in vitro data suggest that parasite killing may be a 
prerequisite for the presentation of antigens found within the parasite’s cytoplasm (60) 
and it is well established that live Leishmania inhibit antigen presentation by their host 
cells (57-59), it is possible that live parasites, rather than those that are being destroyed, 
are responsible for the persistent parasite-dependent immune stimulation and 
maintenance of immunity. Thus, an important future question is what host cells present 
Leishmania antigens: those that contain viable parasites or those that have previously 
killed parasites. In this study, we were unable to find the latter class of host cells, and so 
new approaches will be required to properly address this question. 
If supported by further studies with persistent Leishmania, the stem immunogen model of 
concomitant immunity could also be proposed for other persistent pathogens such as 
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Toxoplasma gondii and herpesviruses. Both persist indefinitely while conferring life-long 
protective immunity against pathology associated with re-infection. In addition, there is 
evidence of at least sporadic sub-clinical reactivation from the persistent/latent stage of 
the infection which would result in the production of antigens for immune stimulation 
(61, 62). Currently, it remains unknown whether these sub-clinical reactivations have a 
role in maintaining immunity or even whether persistent Toxoplasma or latent herpes 
virus infections are required for immunity. However, there is some evidence that at least 
partial reactivation is required to elicit protective immunity against herpesvirus challenge. 
Whereas a replication-deficient γHV68 (ORF50STOP) with a block in immediate early 
gene expression established latency but failed to protect mice from a challenge from WT 
virus (63), a latent attenuated virus (ORF31STOP) capable of partial reactivation 
involving immediate early and early gene expression stimulated robust cellular immunity 
to WT challenge (64), potentially by continually boosting the host’s immune response.  
The fact that live attenuated vaccine lines that can persist and at least partially replicate 
(e.g. L. major lpg2- or γHV68-ORF31STOP) can effectively vaccinate their hosts while 
those that do not partially replicate (e.g. L. major dhfr-ts or γHV68-ORF50STOP) are 
much less effective suggests that the best vaccines may be those consisting of an 
attenuated pathogen capable of long term persistence and replication/reactivation but 
incapable of causing pathology. Such a vaccine may have the added benefit of conferring 
protection to other pathogens as well (2).  
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Figure legends 
Figure 1. BrdU-incorporation assay with Leishmania. A. Graph comparing parasite 
growth as promastigotes in culture media containing BrdU with BrdU-incorporation. 
Data shown is one of three experiments. B. The percentage of BrdU-positive acute-phase 
parasite nuclei after 1, 3, or 6 doses of BrdU in a 24 hour period. Data shown is from one 
experiment, with three mice per treatment. Error bars represent standard deviation. C. 
Representative image of six persistent parasite nuclei (red), two of which are BrdU+ 
(green). Nuclei are stained blue. Scale bar indicates 5µm. D. The percentage of BrdU+ 
parasite nuclei for acute and persistent L. major. Horizontal bars represent the mean for 
all mice. P  value was determined by the Student’s t-test. 
Figure 2. Distribution of persistent parasites within host cells. A. The number of infected 
host cells is plotted as a function of the number of parasites per host cell. ~83% of cells 
infected with persistent parasites contain 3 or less parasites. B. The number of persistent 
L. major plotted as a function of the number of parasites per infected host cell. 78% of 
parasites are within host cells containing 2 or more parasites (‘clusters’). C. Percent of 
acute- or persistent-phase ‘clusters’ (host cells containing 2+ parasites) as a function of 
the percent BrdU-positivity within each cluster. D. Percent BrdU-positivity of acute- or 
persistent-phase parasites as a function of the number of parasites per infected cell. 
Numbers within bars represent the number of infected cells scored for each category. 
Figure 3. Association of persistent parasites with the markers ER-TR7, F4/80, and CD11c 
in footpads and lymph nodes. A. Representative pictures of persistent parasites from the 
footpad (top) or lymph node (bottom) with the markers ER-TR7, F4/80, CD11c 
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individually and F4/80 and CD11c in combination (far right). Parasites are detected with 
a pool of antibodies raised against L. major histone proteins (green). Cell-type markers 
are depicted in red, except for F4/80 in the far-right panel, which is depicted in blue. 
Scale bar indicates 5µm. B. The percentage of persistent parasites within cells expressing 
each marker individually in footpads (FP) or lymph nodes (LN). Each data point 
represents one mouse, and horizontal bars represent the mean for all mice. C. The 
percentage of persistent parasites within macrophages (CD11c-F4/80+) and dendritic cells 
(CD11c+F4/80+/-) in footpads and lymph nodes. 
Figure 4. Persistent L. major survive and replicate within iNOS-expressing cells. A and 
B. Persistent parasites nuclei (green) within an iNOS-expressing (blue), CD11c+ (red, A) 
or F4/80+ (red, B) host cell. C. A persistent GFP-expressing parasite (green) within an 
iNOS-expressing host cell (red). Nuclei are stained blue. The parasite appears intact. D. 
Persistent parasites within an iNOS-expressing cell have intact nuclear genomes. Parasite 
nuclei were detected with antibodies against histone proteins (green), degraded DNA is 
detected by TUNEL-staining (red), and iNOS is stained blue. Absence of co-localization 
of nuclei and TUNEL-staining shows that parasite nuclear genomes are intact. Some 
parasites (white arrows) had TUNEL+ kinetoplasts which would be expected even in 
healthy parasites. Scale bar indicates 5 µm. E. Persistent parasites incorporate BrdU in 
iNOS expressing cells. Parasite histone proteins are stained green, BrdU is stained red, 
and iNOS is stained blue. All three parasites are within an iNOS+ cell and are BrdU+. 
Scale bar indicates 5 µm.  
Figure 5. Comparison of iNOS expression levels by macrophages activated in vitro and 
cells infected with lpg2- parasites in vivo. A. Representative image of starch elicited 
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peritoneal macrophages that were cultured in the presence of interferon-γ and LPS for 24 
h and then stained to detect parasite histones (green) iNOS (red) and nuclei (blue). These 
cells were not infected with L. major. B. Representative image of an infected cell in 
footpad tissue stained identically to the cells in ‘A’. Images of activated macrophages in 
vitro or iNOS-expressing infected cells from footpad tissue were captured by confocal 
microscopy using identical settings. Scale bar indicates 5 µm. C. Comparison of average 
red (iNOS) fluorescence intensity per µm2 within in vitro activated peritoneal 
macrophages (PEM) or iNOS-expressing infected cells from footpad tissue. Each data 
point represents one cell. Black horizontal bars represent mean for all cells. The average 
background intensity is represented by the grey horizontal line. P < 0.001 by the 
Student’s t-test. 
Figure 6. Association of persistent parasites with Arg1 expression. A. Representative 
image of footpad tissue from mice infected with persistent L. major showing an infected 
iNOS+ cell (blue) adjacent to an Arg1+ (red) cell. Parasite nuclei are stained green. B. 
Representative image of log-phase promastigotes stained to detect histones (green) and 
arginase (red). C. Representative image of persistently-infected footpad tissue stained 
identically as the parasites in (B). Scale bar equals 5 microns. D. Analysis of images 
showing relative fluorescence intensity of persistent parasites and promastigotes. This 
value was determined by measuring the sum “red” (arginase) intensity within a circle 
with a 2.28 micron radius centered on the parasite nucleus on confocal images such as 
those in (A) and (B) in which the confocal stack had been compressed into a single plane. 
Grey horizontal bars represent the average background, black bars represent the mean 
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arginase reactivity for all cells. Each data point represents one parasite. *** represents P 
< 10-6 by the Student’s t-test. 
Figure 7. Amastigotes are more resistant to NO than are metacyclic-stage parasites. A. 
Nitrite production (left side) and percent parasite survival (right side) 24 hours after 
infection of control peritoneal macrophages, macrophages activated with interferon-γ and 
LPS, or activated macrophages treated with the iNOS inhibitor L-NIL. B. Nitrite 
production and percent parasite survival measured at 96 hours post-infection and 24 
hours after the addition of interferon-γ and LPS with or without iNOS inhibitor. For all 
plots, the data shown is the average of three independent experiments, and error bars 
represent standard deviation.  
Figure 8. Comparison of the association with CD11c and Arg1 between WT persistent 
parasites, lpg2- 1 month after infection in C57Bl/6 mice, lpg2- >5 months after infection 
in C57Bl/6 mice, and lpg2- 1 month after infection in BALB/c mice. For both plots, each 
data point represents one mouse and the horizontal bars represents the mean for all mice. 
P values were calculated by the Student’s t-test. A. The percentage of parasites within 
CD11c+ cells. For CD11c, the elevated percentage of lpg2- parasites within CD11c+ cells 
does not depend on the duration of the experiment (1 versus 5 months after infection), 
and is also present in BALB/c mice. B. The percentage of parasites associated (either 
within or adjacent to) an Arg1-expressing host cell. In terms of Arg1 association, lpg2- 
within BALB/c mice more closely resembles WT persistent parasites in C57BL/6 mice 
than it does lpg2- in C57BL/6 mice. Thus, the elevated association with Arg1 correlates 
with vaccine failure. Horizontal bars represent the mean for all mice.  
 125  
Figure 9. Stem immunogen model of concomitant immunity. Top: acute-phase L. major 
cell (green oval) within host cell (HC) replicates, with progeny parasites going on to 
infect new host cells where they too will replicate. Middle: quiescent L. major cell resides 
within macrophage or DC (HC). Some quiescent parasites re-enter cell cycle and begin to 
replicate similarly to acute-phase parasites. While some of the progeny parasites 
successfully infect new cells and maintain the infection, most are killed, resulting in 
antigen presentation and maintenance of immunity. Bottom: cartoon of stem cell biology 
in which a quiescent stem cell re-enters the cell cycle in response to some signal and 
divides. Daughter cells can then either remain stem cells or can differentiate, depending 
on a variety of signals. What cues signal quiescent L. major to re-enter the cell cycle or 
how the fate of progeny parasites is determined is unknown, but alterations of the host’s 
immune status would affect the proportions of progeny parasites destined for survival or 
destruction. 
Supplementary figure S1. Slow-growing L. major increase duration of G1 phase. A. Cell 
density of parasites cultured in M199-based (grey) versus RPMI-based (black) media as a 
function of time post inoculation. Parasites in M199 media double every 9.0 hours, 
whereas parasites cultured in the RPMI-based media double every 29.6 hours. B. DNA 
content of cells grown in M199 (grey) and RPMI (black) as assessed by propidium iodide 
(PI) staining intensity. C. Percent of parasites in M199 (grey bars) or RPMI (black bars) 
that are in G1, S, or M/G2 phase in the cell cycle (corresponding to M1, M2, and M3 in 
panel B, respectively). Also shown is the percentage of parasites from each growth 
condition that are BrdU+ 2 hr after the addition of BrdU to the culture media. For the 
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BrdU experiment, error bars represent standard deviation, N = 3 coverslips; > 227 
parasites scored per condition. *** represent p < 3X10-5 by the Student’s t-test.  
Supplementary figure S2. Neither CD11c- (A) nor iNOS-expression (B) correlate with 
the number of persistent parasites per infected host cell. The numbers within the bars 
represent the number of infected cells scored for each category. 
Supplementary figure S3. Positive controls for RELMα staining. A and B. Starch-elicited 
peritoneal exudate cells were either cultured in media without cytokines (A) or cultured 
in the presence of IL-4 and IL-13 (100 U ml-1) for 48 h (B) and then stained to detect 
RELMα (green) or nuclei (blue). Cytokine treatment induced RELMα which was easily 
visualized with anti-RELMα antisera. Scale bar equals 5µm. C. Representative image of 
a footpad tissue section from a foot persistently-infected with WT stained to detect 
parasite histones (green, no parasites visible in this field), RELMα (red) and F4/80 (blue). 
Scale bar equals 5µm. 
Table 1. Persistent L. major replicate comparably within iNOS+ and iNOS- host cells. The 
percentage of both ‘clusters’ and BrdU-positive parasites within iNOS+ host cells is the 
same as the percentage of total parasites within iNOS+ cells.  
Table 2. Comparison of persistent WT and lpg2- parasites in footpad tissue. For the 
summary statistics presented here, E = # of experiments, M = total # of mice, and P = 
total # of parasites. A. N = 2E/7M/1003P. B. N = 3E/10M/616P. C. N = 3E/10M/712P. 
D. N = 3E/10M/1004P. E. N = 3E/3M/346P. F. N = 3E/8M/2535P. G. N = 2E/9M/1105P. 
H. N = 1E/2M/123P. I. N = 3E/5M/477P. J. N = 3E/10M/175 parasite clusters. K. N = 
3E/10M/512 parasite clusters. L. N = 3E/10M/213 parasite clusters. 
 127  
Figure 1 
 
 
 128  
Figure 2 
 
 
 
 129  
Figure 3 
 
 
 130  
Figure 4 
 
 131  
Figure 5 
 
 
 132  
Figure 6 
 
 133  
Figure 7 
 
 
 134  
Figure 8 
 
 135  
Figure 9 
 
 136  
Supplementary figure S1 
 
 137  
Supplementary figure S2 
 
 
 
 138  
Supplementary figure S3 
 
 
 
 139  
Table 1 
 
 
 140  
Table 2 
 
 141
Chapter 4 
 
 
 
Concomitant immunity induced by persistent Leishmania major does not preclude 
secondary re-infection: consequences to the maintenance of natural parasite 
diversity 
 
Michael A. Mandell, and Stephen M. Beverley1 
 
1Department of Molecular Microbiology, Washington University School of Medicine, St. 
Louis MO 63110 USA 
 
1Corresponding author; Dept. of Molecular Microbiology, Washington University School 
of Medicine, Campus Box 8230, 660 S. Euclid Ave., St. Louis MO 63110; Tel: 314-747-
2630; e-mail beverley@borcim.wustl.edu. 
 
 142
Author contributions 
All experiments were performed by M.A.M.  
M.A.M and S.M.B. wrote the text.
 143
Abstract 
Many microbes have evolved the ability to co-exist for long periods of time within other 
species in the absence of overt pathology.  For potential pathogens, evolutionary 
biologists have proposed benefits to the microbe from ‘asymptomatic persistent 
infections’, most commonly invoking increased likelihood of transmission by longer-
lived hosts. Typically asymptomatic persistent infections arise from strong containment 
by the immune system, accompanied by protective immunity; such ‘vaccination’ in the 
presence of a non-sterilizing immune response is termed premunition or concomitant 
immunity.  Here we consider another potential benefit of persistence and concomitant 
immunity:  the ‘exclusion’ of competing super-infecting strains, in a manner reminiscent 
of that seen in lyosgenic bacteriophage in prokaryotes.  To investigate this in the 
protozoan parasite Leishmania major, which provides a superb model for the study of 
asymptomatic persistence, we used isogenic lines of comparable virulence bearing 
independent selectable markers.  One was then used to infect genetically resistant mice, 
yielding infections which healed and progressed to asymptomatic persistent infection; 
these mice were then super-infected with the second marked line.  As anticipated, super-
infection yielded minimal pathology, showing that protective immunity had been 
established.  The relative abundance of the primary and super-infecting secondary 
parasites was then assessed by plating on selective media.  The data show clearly that 
super-infecting parasites were able to colonize the immune host effectively, achieving 
numbers comparable to and sometimes greater than that of the primary parasite.  We 
conclude that induction of protective immunity does not guarantee the Leishmania 
parasite exclusive occupation of the infected host. This finding has important 
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consequences to the maintenance and generation of parasite diversity in the natural 
Leishmania infectious cycle alternating between mammalian and sand fly hosts.
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Introduction 
Persistent host/pathogen relationships are often characterized by a ‘stalemate’ in which 
the host neither succumbs to disease nor is able to completely achieve sterile cure. 
Persistent infections can show varying degrees of pathology, ranging from chronic overt 
disease to asymptomatic infections (1-5). Especially for asymptomatic persistent 
infections, a key component is a strong immune response on the part of the host, which is 
required to keep pathogen numbers in check. In some cases, this immune response also 
serves to protect against pathology resulting from subsequent re-infection by the same 
pathogen, a process known as premunition or concomitant immunity (6-8). 
Long-term host/pathogen relationships carry with them benefits and risks to both 
partners, and have been the subject of a considerable study from an evolutionary 
perspective (9-11). In the case of concomitant immunity, the host benefits by its immune 
system’s ability to control the infection and minimize pathology, as well as protection 
from disease arising from new infections.  However, this comes at the cost of increased 
risk of disease reactivation, typically arising from immunosuppression or stress (1, 4, 12). 
From the pathogen’s perspective, while concomitant immunity decreases microbial 
numbers, it may improve the likelihood of transmission due to the increased longevity of 
the infected host.   
A second potential benefit to the pathogen is ‘exclusivity’, in that concomitant immunity 
may reduce the invasion of the host by other strains or species.  In the case of 
Schistosoma mansoni, concomitant immunity may limit intraspecific competition for 
limited resources (6) (13). A further benefit of exclusivity is transmission, in 
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guaranteeing transmission of the primary infecting line over that of secondary ‘invading’ 
pathogens.   In some respects this scenario resembles that proposed for lysogenic 
bacteriophages, which are generally resistant to super-infection with closely related 
phage (14).  
The protozoan parasite Leishmania major provides an excellent model for investigating 
forces of concomitant immunity and persistence. L. major is transmitted to mammalian 
hosts by the bite of phlebotomine sand flies, and in laboratory mice a range of pathology 
ensues depending on both the particular parasite and mouse strain (15). Infections of 
genetically susceptible mice (such as BALB/c) with most L. major strains yields a 
progressive and fatal infection (15).   In contrast, infection of genetically resistant mice 
(e.g. C57BL/6) initially gives rise to a progressive parasitemia and lesion pathology at the 
site of inoculation similar to that seen in BALB/c mice, but after 4-6 weeks an immune 
response develops which controls both parasitemia and pathology (15, 16). Notably, the 
healed mice are effectively vaccinated and resistant to disease pathology from subsequent 
infections. Following healing, and for the remainder of the host’s life, a small number of 
parasites persist in the skin at the site of inoculation and in the regional lymph node 
draining that site (17). In keeping with concomitant immunity/premonition paradigm, 
these persistent parasites appear to be important for the maintenance of an anti-
Leishmania immune response, as treatment resulting in sterile cure is associated with the 
loss of immunity (18)(19).     The strong protective immunity induced by persistent 
Leishmania is the basis for the ancient practice of leishmanization, in which live, virulent 
parasites are intentionally inoculated in inconspicuous sites of the body to protect against 
natural infection and pathology at other sites (20).  
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Importantly the asymptomatic persistent Leishmania infections of C57BL/6 mice fit 
several criteria relevant to understanding of the benefits and tradeoffs of concomitant 
immunity.  The animals are healthy, and despite the small numbers of persistent parasites 
(< 1000 / mouse), they can be efficiently transmitted to sand flies (21-23). What has not 
been solidly addressed previously in the literature is exclusivity; while it is well known 
that the persistently infected mammalian host is vaccinated from disease pathology, it has 
not been rigorously shown whether the long lived persistently infected host can be 
successfully colonized by secondary parasite exposure. Several studies have evaluated 
the potency of the immune response maintained by persistent parasites by injecting 
parasites in a primary site, waiting for the lesion to resolve, and then injecting parasites 
into a secondary site and determining the parasite load there (19, 24-26). The data from 
these studies would seem to suggest that persistent parasites do not generate “exclusivity” 
in that viable parasites were recovered from the site of secondary challenge.  However, 
the ability of L. major to traffic to sites distant from the site of inoculation (17) raised the 
possibility that these parasites actually arose from the primary infection, perhaps 
accentuated by the transient reactivation of parasites at the primary infection site reported 
by Mendes et al (24).  
To assess the question of exclusivity, we generated parasites derived from the same strain 
of L. major of equal virulence but bearing independent drug resistance markers 
(PHLEO/phleomycin and SAT/nourseothricin).   This were then used in the classic 
infection/challenge persistence model, using the SAT strain as the primary infection, 
which gave rise to the expected lesion/healing/persistence phenomenon, followed by 
injection with the PHLEO strain in the opposite foot.   The results show clearly that under 
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these conditions Leishmania persistence is not accompanied by ‘exclusivity’, in that 
equivalent numbers of both ‘primary’ and ‘secondary’ parasites persisted at their 
respective sites of inoculation.  These data suggest that while persistent L. major 
vaccinate its host from disease pathology, it does not confer exclusivity to the acquisition 
of secondary infecting Leishmania.  This finding has important consequences to the 
maintenance and generation of Leishmania genetic diversity, including that arising 
through sexual processes (27, 28).  
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Materials and Methods 
Parasite strains and culture 
The generation of both the phleomycin resistant parasites (SSU:IR1PHLEO-YFP; 
referred to here as LmjF PHLEO) and the nourseothricin-resistant parasites (SSU:SAT-
TK-LUC; referred to here as LmjF LUC-SAT) used in this study was described 
previously (29, 30). Parasites were grown at 26˚C in M199 medium (US Biologicals) 
supplemented with 40 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid 
(HEPES) pH 7.4, 50 μM adenosine, 1 μg ml−1 biotin, 5 μg ml−1 hemin, 2 μg ml−1 
biopterin and 10% (v/v) heat-inactivated fetal calf serum {Kapler, 1990 #126}. 
Nourseothricin (Jena Bioscience, Jena, Germany) was used at a concentration of 100 
µg/ml and phleomycin (Sigma, St. Louis, MO) was used at a concentration of 20 µg/ml.  
Infective metacyclic-stage parasites were recovered using the density gradient 
centrifugation method (31). 
Mouse infections 
Animal studies were approved by the Animal Studies Committee at Washington 
University (protocol #20090086) in accordance with the Office of Laboratory Animal 
Welfare's guidelines and the Association for Assessment and Accreditation of Laboratory 
Animal Care International. 
Female C57Bl/6J mice (Jackson Labs) were injected subcutaneously in a hind footpad 
with 105 metacyclic stage parasites.  Naïve mice (6-8 weeks old) were injected in the left 
hind footpad.  Secondary injections took place in the right hind footpad at a time point >1 
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month after primary lesions had resolved.  Footpad lesion pathology was measured using 
a Vernier caliper (Mitutoyo).  Luciferase activity was determined as described elsewhere 
(30). Briefly, mice were given a dose of D-luciferin (150 µg gram-1 body weight; 
Biosynth) in PBS 10 minutes prior to imaging with an IVIS 100 imaging system 
(Xenogen Corp). Limiting dilution assays were performed as described previously (32), 
with the addition of phleomycin or nourseothricin as indicated.  
Statistics 
Data are presented as the arithmetic mean ± the standard deviation. P values were 
calculated by the Student’s t-test. 
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Results 
Development of two genetically marked L. major with equivalent virulence in resistant 
mice. 
For this study, we used two L. major Friedlin V1 parasites expressing genes conferring 
resistance to the antibiotics nourseothricin (SAT) or phleomycin (PHLEO). The 
nourseothricin resistant parasites also express firefly luciferase, and will be referred to 
hereafter as “LmjF-LUC-SAT”, while the phleomycin resistant parasites will be referred 
to as LmjF-PHLEO.  To confirm that the LmjF-LUC-SAT and LmjF-PHLEO parasites 
were of comparable virulence in mice, 105 metacyclic-stage parasites were inoculated 
into the footpads of naïve C57BL/6 mice (5 mice/group), and the lesion pathology was 
monitored over time (Fig. 1A). Both lines exhibited disease progression typical of L. 
major / C57BL/6 infections, with lesions developing between 10-17 days post infection 
and reaching their maximum (~1.4 mm in thickness) around 30 days post infection.   
Thereafter the lesions declined, and were completely resolved by 130 days post-infection 
(Fig. 1A).  At this time, mice were sacrificed and the parasite titers in the infected feet 
were enumerated by limiting dilution analysis (Fig. 1B). No significant difference in the 
number of persistent parasites was seen, with LmjF-LUC-SAT and Lmj-PHLEO showing 
a similar range (Fig 1B) and mean (25and 32 parasites / foot; P > 0.45 by Student’s t-
test). We judged these lines to be of comparable virulence and suitable for the following 
tests. 
Healed mice were protected against pathology from subsequent challenge 
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Two experiments were performed in which naïve mice (4-5 mice per experiment) were 
inoculated with 105 purified metacyclic-stage LmjF-LUC-SAT parasites in the left hind 
footpad primary infection site.  These mice formed lesions which spontaneously resolved 
similar to that shown in Fig. 1A (data not shown).   At a time point >1 month later, 105 
metacyclic LmjF-PHLEO parasites were inoculated into the right hind footpad secondary 
infection site.   Footpad swelling of both the primary (L) and secondary (R) injection sites 
were then measured over time.  We also used in vivo imaging of luciferase activity to 
visualize LmjF-LUC-SAT parasites, as a second probe of whether transient reactivation 
of primary parasites occurred (24). 
As expected in both experiments the mice showed good protection, as evidenced by a 
reduction in lesion pathology at the secondary ‘challenge’ site. Although there was some 
between-experiment variation, in both experiments the lesions generated by the 
secondary LmjF-PHLEO parasites were significantly smaller and resolved more rapidly 
than those in naïve mice, (Figure 2A).  We saw no evidence of reactivation by the 
“primary” LmjF-LUC-SATR parasite, as judged by either lesion measurement (Figure 
2B) or in vivo imaging of parasite luciferase (Figure 2C).  Interestingly, in expt. 1 we saw 
a low level of LUC expression in the persistent infection; in other studies we have seen 
this as well, although in general persistent parasite numbers are insufficient for reliable 
imaging (Hickerson & Beverley unpublished). 
Roughly equivalent numbers of both “primary” and “secondary” parasites persist 
We then measured the occurrence of both the primary and secondary- infecting parasites, 
in both infection sites, by limiting dilution assays at day 87 or 139 post-infection. Total 
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parasites were assessed by growth in the absence of drug, while LmjF-LUC-SAT was 
estimated from growth in media containing nourseothricin and LmjF-PHLEO from 
growth in phleomycin. The results from individual mice from both experiments as well as 
the global averages are shown in Fig 3.    
Parasites were recovered from all primary infection sites, ranging from 14 to 504 
parasites/foot, with an average of 282 ± 158 parasites recovered per foot (N = 9).    These 
parasites were exclusively the primary LmjF-LUC-SAT parasite, as they were unable to 
grow in the presence of phleomycin. In one animal the SAT marker was apparently lost; 
similar results have been reported in L. tarentolae and attributed to the genetic plasticity 
of the ribosomal RNA locus where gene conversion has been postulated (33), and we 
have seen this occasionally in other experiments in L. major.     
Parasites were also recovered from the secondary infection site from 8 of the 9 mice, 
ranging from 14 to 785 parasites/foot with an average of 119 ± 156 parasites per foot.   
Importantly, nearly all of the parasites recovered from the secondary infection site were 
the LmjF-PHLEO parasite inoculated there (99 ± 3%).  In only one mouse (#2-5) could 
colonization of the secondary site by ‘primary’ infection site LmjF-LUC-SAT parasites 
be found at all, suggesting that metastasis of parasites from the primary to the secondary 
sites is relatively infrequent. Importantly, the numbers of ‘primary’ infection site LmjF-
LUC-SAT parasites were not significantly different from that seen for the ‘secondary’ 
infection site LMjF-PHLEO parasites (P > 0.08, Student’s T-test). These data show that 
despite ‘vaccination’ as defined by prevention of lesion pathology, the protective 
immunity is not ‘sterilizing’ against secondary infections and does not preclude efficient 
colonization of the infected mouse.
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Discussion 
A number of factors have been proposed to contribute to the maintenance of pathogens 
for long periods of time in the host, including an insufficient immune response and the 
benefits accruing to the pathogen from residing within a longer-lived host thereby 
increasing the likelihood of transmission (9, 11). In many cases this relationship has 
progressed to the point where the pathogen infection is asymptomatic, thereby fulfilling 
the evolutionary dictum that a ‘successful pathogen does not kill its host too quickly”. 
Often this asymptomatic persistence is accompanied by protection from disease induced 
by further infections of the same or related pathogens, a process termed concomitant 
immunity (6). Such a relationship provides benefits to both the pathogen and the host 
through increased longevity of the latter (albeit with some risk of reactivation), and 
increased transmission of the former.    
Leishmania provides an attractive system for the study of concomitant immunity (17, 18, 
24, 34-36) and here we have used this to consider another potential benefit to the 
pathogen, one of ‘exclusivity’. Exclusivity would favor transmission of the primary 
infecting pathogen due to reduction in the ability of secondary infecting parasites to 
establishing in a previously infected host. However, our data show clearly that despite 
induction of a protective immune response able to mitigate disease pathology, secondary 
Leishmania major infections are nonetheless able to establish themselves effectively in a 
previously infected host. While this result may have been anticipated from prior studies 
(19, 25), this is the first time this has been established rigorously for Leishmania using 
genetically marked parasites able to distinguish primary from secondary infections.  
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In our studies we used an inoculum consisting of 105 purified metacyclic parasites.   
While most sand flies transmit less than 600 parasites to mice, a few transmit up to 105 
(22). Thus, the dose used here is not an unrealistic one. In addition, other studies using 
low-dose infections (challenging with 100 metacyclics) yielded results similar to ours in 
that parasites were harvested from the site of secondary infection (19, 24-26). Similarly, 
sand flies convey other factors including saliva and secreted parasite molecules such as 
proteophosphoglycan, both of which typically act to facilitate primary infections (37-40) 
but which can also engender various protective responses (41-42). Thus future studies 
may address this phenomenon in the context of natural sand fly transmission and the 
dissection of the relative roles of sand fly saliva and secreted Leishmania molecules such 
as PPG. 
In our study, the immunity generated by persistent parasites was not sterilizing and the 
average number of “secondary” parasites was not significantly different from that of the 
“primary” parasites (Fig. 3). Nonetheless, the average number of  secondary LmjF-
PHLEO parasites was about 2-fold less than the primary LmjF-LUC-SAT parasites, 
which is consistent with previous studies, such as those of Mendez et al (2004) (24) 
where 10-fold fewer parasites were isolated from the secondary infection site. As noted 
earlier, while these authors did not use genetically marked parasites, our studies show 
that the dissemination of parasites from the primary to the secondary infecting foot is 
relatively infrequent, being seen in only 1/9 infected mice (Fig. 3, mouse #2-5). Thus, 
while secondary infecting parasites may be able to gain access to the previously infected 
host, they may experience a quantitative disadvantage in terms of transmission, especially 
as the efficiency of sand fly infection following feeding on a persistently infected host is 
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already low (~10%) (21). Such a quantitative advantage could over evolutionary time 
provide a strong positive selective force favoring concomitant immunity in addition to the 
previously mentioned factor of host longevity. 
Consequences of ‘nonexclusive’ parasitism to parasite diversity and vaccination 
strategies. 
The finding that the immunity induced by primary L. major infections protects against 
pathology without being sterilizing also has implications for the generation and 
maintenance of Leishmania diversity. In regions where Leishmania is endemic, 
mammalian hosts are likely subjected to multiple independent infections (43, 44). Over 
time, this may result in the host being persistently infected with several genetically 
distinct parasite lines. Once established, mixed infections could then potentially be 
passed to sand flies, which have recently been shown to be the site of parasite genetic 
exchange experimentally (28). Since the frequency of sand flies bearing Leishmania in 
natural populations is relatively low (often just a few per cent) (45-47), maintenance of 
mixed populations in persistent infections may act to increase the frequency at which 
sand flies acquire mixed infections, which thereafter undergo genetic exchange and 
generate diversity. While genetic exchange occurs relatively infrequently on a per 
Leishmania cell basis (<10-4; (28)), Leishmania populations in sand flies are sufficient to 
yield hybrid parasites at high frequencies (25% or greater per fly; (28) Sacks & Beverley, 
unpublished data).   Thus, the lack of ‘exclusivity’ even in the presence of protection 
against disease pathology may result in increased opportunities for genetic exchange and 
the emergence of new disease phenotypes in nature. 
 157
Our data also have some consequences to vaccination strategies. Currently the ‘healed’ 
mouse is considered a ‘gold standard’ for the maintenance of effective immunity against 
disease pathology, and the generation of live-attenuated parasite lines that persist without 
pathology while immunizing against virulent challenge has been a priority in vaccine 
research (48, 49). Our data suggest that such an approach would likely allow virulent 
parasites from subsequent natural infections to establish their own persistent infections 
which would then pose a risk of reactivation. This may provide further impetus for the 
development of vaccines conferring sterilizing, long-lasting protection against both 
pathology and parasitemia. 
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Figure legends 
 
Figure 1.   The LmjF-LUC-SAT and LmjF-PHLEO show comparable virulence in 
infections of resistant mice. C57BL/6 mice (5 per group) were infected with 105 
metacyclic stage LmjF-LUC-SAT or LmjF-PHLEO L. major. N = 1 experiment. A) 
Measurements of lesion pathology (increase in footpad thickness).  Error bars show the 
standard deviation. B) Persistent parasites. 130 days post infection, mice were sacrificed 
and the number of parasites persisting in the footpads was enumerated by limiting 
dilution assay. Horizontal bars show the geometric mean. 
 
Figure 2.  Mice persistently infected with LmjF-LUC-SAT show protection from disease 
pathology by secondary challenge with LmjF-PHLEO parasites. Mice (4-5/group) were 
inoculated with 105 metacyclic LmjF-LUC-SAT parasites in the left hind footpad 
(primary site), following which they developed lesions and then went on to heal (as 
shown in Fig. 1A). At least one month after resolution of the primary lesions, each mouse 
was inoculated in the right hind footpad (secondary site) with 105 metacyclic LmjF-
PHLEO parasites. In these experiments time 0 is when the secondary inoculation was 
performed unless otherwise indicated. For all plots, error bars show the standard 
deviation (n = 4 or 5 in expt. 1 or 2 respectively). A) Lesion pathology at the secondary 
injection site. The dashed line represents the average of the data presented in Fig. 1A for 
infections of naïve mice with LmjF LUC-SAT and LmjF-PHLEO for comparison. B) 
Monitoring of reactivation of pathology at the site of primary infection (left foot). By 
measuring total footpad thickness. C) Monitoring of reactivation of the primary LmjF-
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LUC-SAT parasites at the primary (♦,■) or secondary (◊,□) infection sites site by 
bioluminescent imaging of luciferase expression in vivo; experiment 1 (♦,◊); experiment 
2 (■,□). The upper grey dashed line represents the level of luciferase activity normally 
seen in C57BL/6 mice at peak parasitemia (~7 x 107 photons per second), and the lower 
grey dashed line shows the background typical in these experiments (~5 x 103 photons 
per second).  
 
Figure 3.  Retention of both primary and secondary infecting parasites following 
secondary challenge despite protection from disease pathology. The graph plots the 
number of persistent parasites present in sites of primary and secondary Leishmania 
infections >10 weeks post secondary challenge as assessed by limiting dilution analysis 
in unselective (white bar), nourseothricin-containing (gray bars; resistance mediated by 
SAT marker) or phleomycin-containing (black bars; resistance mediated by PHLEO 
marker) as described in the methods.  The number of parasites in the primary infection 
site (LmjF-LUC-SAT inocula) is displayed in the top graph, and the number of parasites 
in secondary infection site (LmjF-PHLEO inocula) foot is displayed in the bottom graph.  
The numbers between the two graphs represent the mouse identification number 
(experiment number-mouse number). “Avg.” represents the mean for all mice.  
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Chapter Five 
 
Conclusions and future studies 
 
 
 
This chapter was entirely written by Mike Mandell. 
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Introduction 
During the course of my thesis work, I sought to address three main questions. The first 
question, as presented in chapter 2, was whether metacyclic-stage parasites differentiate 
into the amastigote stage within dendritic cells and whether the promastigote-specific 
virulence factor LPG is lost within these cells or retained for potential subsequent transfer 
to macrophages. Chapters 3 and 4 focus on the life-long asymptomatic persistent 
infections that occur following healing of lesion pathology. The focus of chapter 3 is 
primarily to address whether or not persistent parasites replicate as well as to determine 
their localization. In addition, I sought to determine if the attenuated lpg2- line resembled 
wild type persistent parasites so as to be a model of parasite persistence that would 
facilitate future studies by decreasing the lag time between mouse infections and 
experiments. Finally, in chapter 3 I asked whether the immunity maintained by persistent 
L. major is sufficiently strong to be sterilizing against super-infecting parasites, thus 
gaining the persistent parasites exclusive ownership of and transmission from their host. 
The main conclusions from these studies are presented here in the following three 
sections. The remaining sections highlight a number of interesting questions raised by the 
studies presented in this dissertation that should be the focus of future work. The first of 
these involve testing aspects of the stem immunogen model of concomitant immunity that 
was presented in chapter 3 and that will be discussed again below. In addition, two other 
future aims are presented, both dealing with the capacity of lpg2- L. major to vaccinate 
BALB/c, but not C57BL/6 mice, against virulent challenge (1, 2).  
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The timing of amastigogenesis-related changes in L. major is variable, depending on the 
host cell type infected, allowing for the retention of the LPG, a virulence factor critical to 
parasite establishment in mice (chapter 2) 
My studies showed that the timing of some developmental changes that are associated 
with parasites differentiating from the infectious metacyclic stage to the intracellularly 
replicating amastigote stage differs depending on the type of host cell that is infected. In 
these studies, I infected peritoneal macrophages, bone marrow macrophages, and bone 
marrow dendritic cells with metacyclic stage parasites and compared the sequence and 
timing of parasite differentiation as assessed by six markers that are differentially 
expressed between the two stages of the parasite life cycle. In general, the sequence of 
amastigote marker induction was similar in all three cell types and amastigote-like 
phenotypes for each marker individually were present on at least some parasites in all cell 
types by 24 hours after infection. These data suggest that the parasites do not remain 
metacyclics within the different cell types, including within dendritic cells which are one 
of the first types of cells to be infected in vivo (3). In fact, amastigote marker induction 
was similar in all three host cell types in terms of the down-regulation of paraflagellar rod 
(PFR), the induction of two unidentified amastigote-specific antigens, and in the 
induction of a YFP transgene which is down-regulated in amastigotes. 
However, fewer parasites within the bone marrow derived cells re-entered the cell cycle 
as assessed by BrdU incorporation and lost LPG expression as compared with the 
reference peritoneal macrophages. By 48 hours post-infection, most parasites within 
peritoneal macrophages were LPG-negative. In contrast, 37% or more of the parasites 
within the bone marrow cells retained high-level LPG expression at 72 hours after 
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infection. These data imply that the timing of differentiation as assessed by these markers 
is somewhat plastic and dependent on the type of host cell infected. Alternatively, the 
parasites within bone marrow derived cells may undergo an incomplete differentiation in 
which relatively early developmental changes take place and then the parasites arrest 
their development prior to cell cycle re-entry and LPG loss. Future work could focus on 
what differences between the three host cell types result in the differences seen here. 
These data are important for two reasons. First, they suggest that, under in vivo 
conditions in which parasites appear to be transferred from the first cell types infected 
(including dendritic cells) to macrophages by ~48 hours after infection, macrophages are 
likely to encounter promastigote-specific virulence factors such as LPG which are 
important in the establishment phase of infection. Second, the fact that parasite 
differentiation can be slowed down or even arrested in vitro suggests that parasites may 
also be able to do this in vivo, thus prolonging the duration in which LPG and potentially 
other promastigote-specific virulence factors could interact with host cells to promote 
parasite establishment. In addition to my data, one of the main contributions of my work 
that is presented in chapter 2 is the evaluation of cytological markers of differentiation, as 
such reagents are potentially useful to the field. Uses for these markers could include 
identifying environmental signals that are either positive or negative regulators of 
differentiation or as read-outs for genetic studies of amastigogenesis. 
Studies of the replication and localization of persistent WT and lpg2- L. major in mice 
(chapter 3) 
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As the number of persistent parasites within a mouse remains roughly constant over time, 
I asked whether persistent parasites were replicating or in a quiescent state. My studies 
show that persistent parasites do indeed replicate. Continual parasite replication despite 
constant parasite numbers strongly implies that persistent parasites must also undergo 
destruction. Although persistent parasites do replicate, it appears that they do so less than 
do acute-phase parasites. Further studies suggested that this difference in replication is 
attributable to the presence of a slow or non-replicating sub-population of persistent 
parasites which is not detected in the acute phase. As I was unable to find parasites within 
persistently infected tissue that were obviously undergoing destruction, I assume that all 
of the parasites which were visualized, including those that appear to be poorly 
replicating, are alive. Further studies, which will be described later in this chapter, are 
necessary to test this assumption in order to rule in our out the existence of a quiescent 
sub-population. Until that time, I propose that persistent parasites can be classified into 
three sub-groups: replicating persistent, quiescent persistent, and terminal persistent 
(parasites that are destined for destruction).  
An obvious question arising from the classification of persistent parasites into these three 
groups (replicating, quiescent, and terminal) is whether the different classes of parasites 
are found within different host cell types. The localization of persistent parasites has been 
a somewhat controversial issue in the field, at least in part resulting from the “safe cell” 
hypothesis that was proposed by Bogdan et al (2000) (4). This model assumes that 
macrophages would be unfit host cells for persistent Leishmania owing to their ability to 
express high levels of iNOS. Instead, Bogdan showed that some persistent parasites in 
lymph nodes were within fibroblasts, which typically were iNOS-negative. These 
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fibroblasts were proposed to be a crucial reservoir in which parasites could reside during 
the persistent phase. Although no other study has been published that supports or refutes 
the safe cell model, this study has been cited 87 times and the safe cell model has to some 
extent become dogma. Contrary to Bogdan’s data, I found very few persistent parasites 
within fibroblasts and instead found that the vast majority of persistent L. major to be 
within macrophages and dendritic cells in both footpad and lymph node tissue. This 
finding does not support the essentiality of fibroblasts as safe cells for persistent 
Leishmania. In addition, although many of the infected host cells expressed iNOS, the 
parasites within iNOS+ cells appeared to be viable and replicating, calling into question 
the central assumption of the safe cell model that iNOS-expressing host cells cannot 
support parasite survival. Therefore, my data do not support a safe cell model in which 
persistent parasites “hide-out” from iNOS-expressing cells within fibroblasts. 
Instead, my data suggest that persistent infections are likely quite dynamic systems 
driven by constant parasite replication in which progeny parasites can have one of two 
fates. Some parasites go on to infect a new macrophage or dendritic cell in which they 
survive as either replicating or quiescent forms, thus maintaining the persistent infection. 
Other progeny go on to face destruction in other macrophages or dendritic cells, which 
keeps parasite numbers from increasing. I propose that antigens from those killed 
parasites could be presented and may have a role in stimulating the immune system and 
consequently maintaining protective immunity. If this is the case, the replicating 
persistent parasites are crucial both for their own self-regeneration as well as constantly 
providing a continual immune boost in the form of progeny parasites that are destined for 
killing. In chapter 3, I compare this model with stem cells, in which a stem population 
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replicates with some daughter cells remaining pluripotent and maintaining the stem cell 
population while other daughter cells become terminally differentiated. As will be 
discussed later in this chapter, future work should focus on testing whether or not parasite 
killing is important for antigen presentation by infected cells. 
Another aim of the work presented in chapter 3 was to compare the replication and 
localization of attenuate lpg2- parasites, which previously have been proposed as a model 
that would allow for more rapid establishment of persistent infections (5), with what is 
seen with wild type persistent parasites. lpg2- parasites resembled persistent WT parasites 
in terms of the percent of parasites labeling with BrdU, indicative of similar replication. 
Furthermore, my analysis suggests that both quiescent and replicating sub-populations of 
lpg2- exist in mice. Similar to wild type persistent parasites, lpg2- parasites are found 
within macrophages and dendritic cells, many of which express high levels of iNOS 
protein. However, I observed two differences in the nature of the host cells infected by 
lpg2-: first that a higher percentage of lpg2- parasites were found in DCs, and second, in 
that  more lpg2- -infected host cells or a host cell directly adjacent to them expressed 
arginase 1 (Arg1) that was seen with persistent WT parasites. Arg1 association correlated 
inversely with the ability of lpg2- to vaccinate mice against virulent challenge, as the 
association between lpg2- and Arg1 was seen in C57BL/6 mice which are not vaccinated 
by lpg2-, but was not seen in BALB/c mice, which are strongly protected by lpg2- (1, 2). 
Taken together my data supports the use of lpg2- as a model of WT persistence, 
especially in the BALB/c mouse.  
Do persistent parasites use their host’s protective immunity to exclude super-infecting 
competitors? (Chapter 4) 
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A number of potential benefits have been proposed for pathogens which immunize their 
hosts. In chapter 4, I proposed another such benefit that persistent L. major might achieve 
through protecting their hosts against subsequent infection: that of exclusivity. If the 
immunity that is maintained by persistent parasites is sufficient to prevent the 
establishment of super-infecting parasites, then the first parasite to infect a host would 
gain a monopoly on that host, which from then on could only transmit the genome of the 
first parasite to infect. The ability of a parasite to gain exclusivity would be highly 
selective and would be predicted to move quickly through a population. Using genetically 
marked parasites of equivalent virulence, I showed that persistent parasites do not gain 
exclusivity, but rather that super-infecting parasites can become established and persist in 
similar numbers within their host. These data suggest that, in nature, a host could 
potentially be infected with parasites derived from multiple independent infections, with 
the parasites potentially being genetically and phenotypically distinct from each other. 
Such mixed infections could then be passed on to sand flies, which have been shown to 
support sexual recombination of L. major (6).   
Is there a quiescent sub-population of persistent parasites and, if so, do the quiescent 
persistent parasites differ from replicating persistent parasites or acute-phase 
amastigotes? 
As discussed above, my data suggest that there are two populations of persistent 
parasites, one that is actively replicating and one that appears to be replicating slowly if at 
all. One interpretation of this is that the slow replicating population represents a group of 
viable parasites that replicate slowly either because they are in sub-optimal conditions for 
growth or because they have exited the cell cycle and are in some sort of arrest or stasis. 
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Another interpretation is that these parasites do not undergo replication as assessed by 
BrdU labeling because they are the parasites that are dead or dying, and were not 
identified as such previously because the assays used in chapter 3 (TUNEL and 
observation of morphological integrity) are simply the wrong assays of parasite 
destruction. Thus, an important question is whether or not the parasites that are herein 
referred to as quiescent persistent are actually alive. Perhaps the best approach to 
demonstrate viability would be through some kind of metabolic labeling that would label 
all living parasites but would not label host cells. One possible approach takes advantage 
of a tunable protein expression system in which a reporter protein such as DsRed fused to 
a destabilization domain (DD) can be stabilized in the presence of a small molecule that 
can be administered to mice (7, 8). Mice could be infected with transgenic parasites 
expressing DD-DsRed. Once the infections have entered the persistent phase, the mice 
could be dosed with the small molecule Shield1, which would stabilize the DD and allow 
for DsRed protein to accumulate within parasites that are actively undergoing 
transcription and translation (in other words, alive). As discussed in chapter 3, the 
quiescent parasites tended to be in host cells containing one to three parasites, and so the 
absence of DsRed protein in parasites within such host cells relative to what is seen in 
host cells containing four or more parasites would indicate that the parasites that I refer to 
as quiescent are in fact dead. Alternatively, if DsRed-positivity of the parasites is 
independent of the number of parasites per infected cells, this would argue the opposite. 
If the quiescent persistent parasites are shown to be viable, the next question to be 
addressed is whether or how they differ from replicating persistent parasites. Potentially, 
quiescent persistent parasites differ from replicating persistent parasites only in terms of 
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replication, possibly because the replicating persistent parasites are in an environment 
more suitable to rapid replication. Alternatively, the quiescent persistent parasites may in 
fact constitute a different stage of the parasite life cycle in a manner consistent with 
quiescent Toxoplasma, herpes viruses, or Mycobacteria, all of which have gene 
expression profiles that are specifically devoted to persistence (9-11). To address this 
question, the gene expression profiles of quiescent persistent parasites (enriched in small 
clusters) versus replicating persistent parasites (enriched in large clusters) could be 
determined by microarray after RNA isolation by laser capture procedures. Additionally, 
similar studies could be performed to compare the gene expression profile of persistent 
parasites with that of acute-phase amastigotes. The purpose of these studies would be to 
first, determine if Leishmania also has a stage of its life cycle that is specifically devoted 
to persistence, and second, to identify markers that would distinguish persistent parasites 
from acute-phase parasites or quiescent persistent parasite from replicating persistent 
parasites. 
Is parasite killing important for effective antigen presentation? 
As has been mentioned elsewhere in this dissertation, persistent parasites have a role in 
maintaining protective immunity (12, 13). Presumably, a key component of this role is 
constant presentation of parasite antigens to the immune system. In the stem immunogen 
model, I propose that some parasites become “terminally differentiated” (are killed) and 
that the antigens that are presented are derived from these parasites rather than the 
replicating “stem” Leishmania. It is reasonable to assume that host cells containing dead 
Leishmania may more effectively present antigen than do host cells containing live 
parasites, as live Leishmania have been shown to inhibit antigen presentation by their 
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host cells (14-16). However, this assumption has not been proven and it is possible that 
just as much antigen is presented by host cells containing healthy, replicating parasites as 
is presented by host cells that contain antigens from parasites that they had previously 
killed. Therefore, future studies should determine if intracellular parasite killing is a 
prerequisite for effective antigen presentation and T cell stimulation as this question has 
not been directly addressed in the literature. For these studies, macrophages or dendritic 
cells could be infected with transgenic parasites expressing the model antigen OVA and 
with thymidine kinase derived from herpes simplex virus. Some of the infected cells 
could then be cultured in the presence of gangcyclovir, which should kill the parasites but 
have minimal effects on the host cells. If host cells containing killed parasites more 
efficiently present antigen, then OVA-specific OT-II T cells should proliferate more after 
co-culture with the gangcyclovir-treated infected cells than after co-culture with the 
untreated infected cells.   
What is the role of host arginase 1 in vaccine failure of lpg2- -infected C57BL/6 mice? 
When lpg2- -infected BALB/c mice are ‘challenged’ with virulent parasites, they are able 
to prevent the virulent parasites from replicating to high titers and are protected from 
disease pathology (1). However, lpg2- parasites are not sufficient to confer such 
resistance to C57BL/6 mice unless the parasites are co-injected with CpG DNA as an 
adjuvant (2). Data presented in chapter 3 demonstrates that association of parasites with 
host arginase 1-expressing cells was a negative correlate of immunity to pathology.  In 
other words, a higher percentage of parasites in (C57BL/6 harboring lpg2-) which were 
shown to be poorly protected in other studies, were either within or adjacent to an Arg1-
expressing host cell than were parasites within strongly protected C57BL/6 mice 
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harboring WT persistent parasites or BALB/c mice harboring lpg2- parasites (Table 5-1). 
While this correlation does not prove that Arg1 expression results in vaccine failure, there 
is ample evidence in the literature that suggests such a causal relationship is plausible 
(17-24). 
Like all arginases, Arg1 catalyzes the hydrolysis of L-arginine resulting in the production 
of urea and L-ornithine, which is the precursor for polyamine synthesis (25). Cells 
expressing high levels of Arg1 have been shown to quickly deplete L-arginine from 
culture media and are thought to also have the capacity to deplete arginine in their micro-
environment in vivo (26). L-arginine depletion has been shown to diminish effector T-cell 
function by decreasing the number of T-cell receptors present on the cell surface and by 
preventing T-cell proliferation in response to antigen stimulation (23, 26, 27). These 
results have been confirmed in L. major-specific T-cells, which were also shown to 
express lower amounts of interferon-γ upon antigen stimulation under conditions of 
arginine-deprivation (24). In addition, depletion of essential amino acids including 
arginine is reported to induce naïve T-cells to adopt a regulatory phenotype (20). As 
adoptive transfer of Leishmania-specific Treg cells leads to reactivation of persistent L. 
major infections (28), an increase in these cells would also likely be disease-promoting in 
the event of virulent L. major challenge. Arginine depletion may also have a role in 
preventing the generation of nitric oxide (NO), an effector molecule required for the 
control of L. major infection in vitro and in vivo (29-31). NO is generated through the 
enzymatic activity of iNOS, which uses L-arginine as a substrate (27). Numerous studies 
demonstrate that reduction in arginine availability results in corresponding reductions in 
NO output by iNOS-expressing cells (27, 32-35). In addition to these effects of arginine 
 182
depletion in iNOS activity, arginine depletion has also been demonstrated to have effects 
on NO production by decreasing iNOS expression (22).  
Another consequence of elevated levels of Arg1 expression in association with lpg2- 
parasites could be an increase in the amounts of polyamines which appear to be limiting 
for L. major early in mouse infection, thus facilitating parasite growth (27, 34, 36). In 
addition to being potentially beneficial to the parasite in terms of nutrition, polyamines 
have also been shown to attenuate iNOS expression and function (17-19).  
Some of the mechanisms mentioned above by which Arg1 expression could result in 
vaccine failure by lpg2- (e.g. effects on NO production or providing polyamines to 
“challenge” parasites) act directly upon the parasite’s environment and thus depend on 
the up-regulation of Arg1 in or the recruitment of Arg1-expressing cells to the challenge 
site, a point which has not yet been established. Other mechanisms, such as those 
involving T-cells, act indirectly on the parasite’s environment and would not require 
close association between parasite-infected cells at the challenge site and Arg1+ cells. 
Future work should aim to increase the size of the data-set demonstrating a correlation 
between Arg1-association and vaccine failure. While my data suggests such a correlation 
exists, more data points are needed to firmly conclude this point. To this end, 
experiments could be performed to determine the level of Arg1 association with lpg2- in 
C57BL/6 mice that have been treated with CpG DNA as an adjuvant and that are strongly 
protected against pathology from new infections. In addition to lpg2-, several other L. 
major lines exist which persist indefinitely without causing pathology (e.g. fbp- or iscl-), 
but studies regarding their ability to vaccinate different strains of mice has not been 
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published (37, 38). Studies could be performed with these parasite lines to determine 
their vaccination status in different mouse strains and the level of Arg1 association. If 
after these studies the correlation between Arg1 association and vaccine failure is still 
apparent, future work should focus on determining if Arg1 association is causative of 
vaccine failure as outlined below.   
To determine if the observed Arg1-association causes vaccine failure, the ability of lpg2- 
parasites to vaccinate Arg1-deficient mice and their WT litter-mates of the appropriate 
mouse strain (C57BL/7) could be assessed. Fortunately, such mice have been generated: 
Arg1 has been deleted from most macrophages and neutrophils in Arg1 flox/flox; LysMcre 
mice (39).   If Arg1 is responsible for vaccine failure in C57BL/6 mice, then arginase-
deficient Arg1 flox/flox; LysMcre mice should be protected from virulent challenge by prior 
lpg2- infection while their wild type siblings would remain susceptible.  
If Arg1 expression is found to be responsible for vaccine failure, future work should 
focus on understanding the mechanism by which this occurs. As mentioned above, the 
“direct” effects of Arg1 depend on its localization at the challenge site. Thus, if Arg1 
results in vaccine failure by attenuating NO production or increasing the amount of 
polyamines available to the parasites, then the expression of Arg1 within the challenge 
site of lpg2- -infected C57BL/6 mice should be greater than that of “immune” lpg2- -
infected BALB/c mice. If this is the case, future studies could focus on potential 
differences between “immune” and non-imnune” lpg2- -infected mice in terms of iNOS 
expression and NO production at the challenge site.  
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If lpg2- vaccinates Arg1 conditional knock-out mice but not their WT litter-mates, then 
this system will allow for a good way to determine if Arg1 affects T-cell function by the 
use of adoptive transfer experiments of T-cells from lpg2- -infected Arg1 flox/flox; LysMcre 
mice and WT Arg1 flox/flox mice into naïve mice followed by virulent L. major challenge. 
As previous studies have demonstrated that such transfers of T-cells from immune mice 
confer protection to naïve mice (40), the T-cells from the “immune” Arg1 flox/flox; 
LysMcre mice would be expected to be protective. If Arg1-induced vaccine failure results 
from altered T-cell phenotypes and not from the “direct” effects described above, then 
adoptive transfer of T-cells from lpg2- -infected Arg1 flox/flox would not be expected to 
confer protective immunity. If this is indeed the result, then modifications of this 
adoptive transfer system could be made to further define how Arg1 affects T-cells 
resulting in vaccine failure. 
Use of lpg2- vaccination model to identify anti-Leishmania effectors in addition to NO 
As mentioned above, nitric oxide is clearly important in controlling L. major infections in 
vitro and in vivo (29-31). As such, cells expressing iNOS have been considered likely 
sites of parasite destruction (4, 41-43). However, in Chapter 3 I present data showing that 
both lpg2- and WT persistent parasites were capable of surviving and replicating within 
host cells expressing high levels of iNOS. This surprising result raises the possibility that 
while NO is necessary for Leishmania killing, it may not be sufficient and other effector 
molecules in addition to NO are also required.    
As described above and in table 5-1, infection of C57Bl/6 mice with lpg2- parasites does 
not lead to protective immunity against subsequent virulent challenge while lpg2- 
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infection of BALB/c mice does confer protection. Thus, it is reasonable to assume that 
the host cells containing L. major at the challenge site in “immune” mice (lpg2- // 
BALB/c) differ in some way relevant to Leishmania killing from L. major-containing 
cells in “non-immune” mice (lpg2- // C57BL6). One possible difference is in terms of 
iNOS expression. However, my data show that ~70% of lpg2- parasites are within iNOS+ 
host cells in either BALB/c (“immune”) or C57BL/6 (“non-immune”) mice. If the 
phenotype of infected cells at the challenge site resembles that of cells at the site of 
primary lpg2- infection, then the levels of iNOS expression by cells at the challenge site 
may not differ with vaccination status. Differences in the ability of Leishmania-
containing cells to kill parasites in “immune” versus “non-immune” mice despite similar 
levels of iNOS expression and NO generation would imply that other factors are also 
involved. As such, a global comparison of the infected host cells at the challenge site 
between “immune” and “non-immune” mice may present a good system to identify these 
factors.  
Some of the differences between the Leishmania containing cells in “immune” versus 
“non-immune” mice could be in terms of the activity of constitutively-expressed proteins 
which are normally in an inactive form but are activated under conditions of infection by 
post-translational modification. Alternatively, the relative expression of genes involved in 
Leishmania killing may differ between Leishmania-containing cells in “immune” mice 
versus those in “non-immune” mice. I propose to use a microarray-based approach to 
focus on the latter class of factors. For these studies, I will use C57BL/6 that have been 
simultaneously injected with lpg2- parasites and with CpG DNA as an adjuvant and 
which are strongly protected against virulent challenge (2) as the “immune” mice, thus 
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eliminating mouse strain as a potentially confounding variable in comparisons with “non-
immune” lpg2- -infected mice of the same strain.   
Several control experiments must be performed prior to trying to obtain RNA from 
infected cells. First, it will be important to establish the appropriate time frame at which 
parasite killing is occurring in “immune” mice but not in “non-immune” mice. It will also 
be important to eliminate the possibility that the difference in the ability of “immune” 
versus “non-immune” mice to kill L. major results merely from the relative inability of 
“non-immune” mice to generate NO at the challenge site. If the “immune” and “non-
immune” lpg2- -infected mice generate comparable levels of NO following virulent 
challenge, then experiments can proceed.  
RNA from infected host cells of both “immune” and “non-immune” mice would then be 
harvested by laser-capture procedures at the earliest time-point at which parasite killing is 
seen in “immune” mice, and differences in gene expression would be detected by 
microarray. While such an approach would miss those proteins whose anti-Leishmania 
activity is affected by post-translational modification, it may identify novel anti-microbial 
pathways that may also be important for the control other intracellular pathogens in 
addition to Leishmania.  
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Introduction 
One approach for identifying novel Leishmania factors involved in mammalian virulence 
is by the identification of molecules that are specifically expressed by the amastigote 
stage of the parasite’s life cycle, as such molecules are unlikely to have roles in cellular 
“house keeping” or in sand fly virulence. Additionally, molecules with amastigote-
specific expression are good candidates for reverse genetic studies, as their synthesis is 
unlikely to be essential to promastigote-stage parasites, which is the stage of the parasite 
life cycle most easily cultured in a laboratory setting and in which transfection 
experiments are typically performed (1). More than two decades ago, Charles Jaffe 
developed monoclonal antibodies that specifically recognize Leishmania major 
amastigotes, but neither the molecules recognized by these antisera, nor their functions, 
have been determined (2). In Chapter 2 of this thesis, I developed the use of two of these 
antisera, referred to as T17 and T18, as “amastigote markers”. In that work, we showed 
by immunofluorescence microscopy that the two amastigote-specific antisera had 
different sub-cellular localization patterns, and hence recognized different antigens. We 
also found that the T17 and T18 reactive molecules are induced by 8 hours after infection 
of host cells, ultimately labeling >90% of the parasites by 11 hours post-infection. In this 
work, we further describe the sub-cellular localization of the molecules recognized by 
these two antisera by immunoflourescence and immunoelectron microscopy and identify 
conditions that result in high level expression of the T17 and T18 antigens in by >40% of 
parasites axenic culture for proteomic analysis. 
 
 198
Materials and Methods 
 Parasite culture 
L. major Friedlin V1 strain (MHOM/IL/80/Friedlin) parasites expressing YFP (yellow 
fluorescent protein; SSU:IR1PHLEO-YFP) were generated as described elsewhere (3). 
These parasites were grown at 26˚C in M199 medium (US Biologicals) supplemented 
with 40 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) pH 7.4, 
50 μM adenosine, 1 μg ml−1 biotin, 5 μg ml−1 hemin, 2 μg ml−1 biopterin and 10% (v/v) 
heat-inactivated fetal calf serum (1). For experiments in which amastigote marker 
induction was assayed in the absence of host cells, 10 ml of parasites that had been in 
stationary-phase for two days (2X108 cells) were pelleted and resuspended in 30 ml pre-
warmed RPMI 1640 (Invitrogen) and kept in a 37˚C for 24 hours with 5% CO2. 
Macrophage infections 
Peritoneal macrophages (PEMs) were elicited by a peritoneal injection of potato starch 
into female C57Bl/6J mice (6-10 weeks old; Jackson Labs) harvested as described, plated 
on glass coverslips, and maintained in DMEM (Invitrogen) containing 10% FCS and 2 
mM L-glutamine in a 37˚C  incubator with 5% CO2 (4). The day after the PEM 
isolations, infective metacyclic-stage parasites were recovered using the density gradient 
centrifugation method (5) and opsonized with serum from C5-deficient mice prior to 
being added at a parasite to PEM ratio of 5:1. Extracellular parasites were removed 2 
hours after infection by extensive washing. Infected PEMs were provided with fresh 
media daily, and samples were prepared for microscopy 3 days after infection. 
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Antibodies, immunofluorescence staining and microscopy 
T17 and T18 antisera were provided by C. Jaffe as lyophilized mouse ascites fluid. For 
these studies we used T17 that was prepared 1/7/1996 and T18 that was prepared 
2/8/1991.  
Samples of infected PEMs on coverslips were fixed in 4% (w/v) paraformaldehyde (PFA) 
in phosphate-buffered saline (PBS) for 10 minutes. In vitro “differentiated” parasites 
were were fixed in 4% (w/v) PFA in phosphate-buffered saline (PBS) for 2 minutes, and 
then the parasite/PFA suspension was diluted 10-fold in PBS. Samples were washed in 
PBS, and then blocked and permeabolized in PBS containing 5% (v/v) normal goat sera 
(Vector labs) and 0.1% (v/v) Triton-X-100 for 30 min (blocking buffer). Parasite nuclei 
were then stained with a pool of rabbit antibodies raised against L. major histones H2A, 
H2Avariant, H2B, H3, and H4 (pooled at a ratio of 3:2:3:3:1 by titer) and used at a dilution of 
1:750 in blocking buffer (Wong and Beverley, in preparation). T17 or T18 antibodies 
were diluted 1:400 in blocking buffer. After a one hour incubation in primary antibodies, 
unbound antibody was washed off in PBS and primary antibodies were detected with 
Alexafluor488 goat anti-mouse and Alexafluor555 goat anti-rabbit (Invitrogen, both used 
at a concentration of 2 μg ml−1). DNA was detected with Hoechst 33342 (Invitrogen, 
used at a concentration of 5 μg ml−1) for wide-field microscopy or TOPRO-3 (Invitrogen, 
used at a concentration of 2 μM) for confocal microscopy. After a 40 minute incubation, 
samples were washed with PBS and mounted in ProLong Gold (Invitrogen).  
In vitro “differentiated” parasites were were fixed in 4% (w/v) PFA in phosphate-
buffered saline (PBS) for 2 minutes, and then the parasite/PFA suspension was diluted 
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10-fold in PBS. Fixed parasites were then spun down and resuspended in PBS at a 
concentration of 8 X 106 parasites per milliliter. Parasites (4 X 106) were then adhered to 
glass cover slips by centrifugation. Blocking, permeabilization, and antibody staining was 
then performed as described above. 
Microscopy was performed on an Olympus AX-70 wide-field fluorescence microscope or 
a Zeiss 510 META confocal laser scanning microscope. Cutoffs for saturation and 
background levels were adjusted with Photoshop software (Adobe). 
Immuno-electron microscopy 
These studies were performed by Wandy Beatty in the Microbiology imaging facility. 
For immunolocalization by transmission electron microscopy, infected cells were fixed in 
4% paraformaldehyde/0.05% glutaraldehyde (Polysciences Inc., Warrington, PA) in 
100mM PIPES/0.5mM MgCl2, pH 7.2 for 1 hr at 4˚C.  Samples were infiltrated 
overnight in the cryoprotectant 2.3M sucrose/20% polyvinyl pyrrolidone in 
PIPES/MgCl2 at 4˚C. To permeabilize cells for antibody labeling samples were plunge-
frozen in liquid nitrogen and subsequently thawed in PBS at room temperature. This 
technique was confirmed to permeabilize the host cell membrane and intracellular 
organelle membranes. Samples were probed with the primary antibodies at 1:250 
dilutions followed by FluoroNanogold anti-mouse Fab (1:250; Nanoprobes, Yaphank, 
NY) and silver enhancement (Nanoprobes HQ silver enhancement kit). Samples were 
washed in phosphate buffer and post-fixed in 1% osmium tetroxide (Polysciences Inc., 
Warrington, PA) for 1 hr.  Samples were then rinsed extensively in dH20 prior to en bloc 
staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 hr. 
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Following several rinses in dH20, samples were dehydrated in a graded series of ethanol 
and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a 
Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained 
with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission 
electron microscope (JEOL USA Inc., Peabody, MA). All pre-labeling experiments were 
conducted in parallel with omission of the primary antibody. These controls were 
consistently negative at the concentration of Nanoprobes-conjugated secondary 
antibodies used in these studies. 
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Results and discussion 
T17 epitope localizes to the amastigote flagella and surface and is also found in vesicles 
within the host cell cytoplasm 
To determine the localization of the antigen recognized by mAB T17, we stained PEMs 
that had been infected for 72 hours with mAB T17, as well as antisera raised against L. 
major histone proteins to localize parasite nuclei, and with Hoechst 33342 to detect DNA 
(Figure 1A). The most intense T17 reactivity presented as a line at the parasites anterior 
end proceeding outward from the kinetoplast to the anterior pole of the cell. This staining 
pattern is consistent with mAB T17 recognizing the amastigote flagella, the length of 
which is almost entirely within the flagellar pocket (6). Less intense staining was also 
seen on the surface of amastigotes. This staining pattern was apparent on 91% of T17+ 
parasites scored (N = 222 parasites). As shown in Figure 1B and C, this localization 
pattern was also found by immuno-electron microscopy.  
Interestingly, mAB T17 reactivity was not limited to the parasite itself, but was also 
showed a punctate staining pattern within the cytoplasm of infected, but not uninfected, 
macrophages (Figure 2A). Immuno-electron microscopy images revealed that, in many 
cases, the T17 antigen was concentrated just outside the phagolysosomal membrane at 
the distal tip of the amastigote flagellum (Figure 2B) and was also found within 
membranous compartments further away from the parasite-containing phagolysosome 
(Figure 2C).  
In summary, these results suggest that the mAB T17 antigen localizes predominantly to 
the amastigote flagellum, and is somehow translocated to the parasite’s surface and out of 
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the phagolysosome. These data are provocative when considered in the context of two 
recent studies from other laboratories. First, Reiner’s laboratory has suggested that a 
number of Leishmania proteins are delivered to the host cell within ‘exosomes’, which 
could modulate immune responses by host cells (7, 8). One concern from these data is 
that the exosome composition when evaluated by proteomics is qualitatively similar to 
that of total Leishmania proteins, albeit with modest quantitative differences. Second, 
Gluenz et al (2010) have proposed the existence of a ‘flagellar’ synapse in the parasites  
orient their flagella such that the distal tip is in intimate contact with the phagolysosomal 
membrane (6). Connecting these results is the observation of exosomes budding off of the 
distal tip of Chlamydomonas flagella (9), suggesting a secretory role for this organelle. 
Potentially antigen T17 represents an example of a stage-specific parasite ‘cargo’ 
delivered by the flagellar route. This will be pursued in the future by the Beverley 
laboratory. 
T18 epitope localizes to amastigote surface and a novel structure at the parasite’s 
posterior pole 
Figure 3 shows the localization of the antigen recognized by mAB T18 on amastigotes. 
The parasite’s surface clearly is recognized by the antibody. In addition, most parasites 
(78%, N = 187) have a region of intense staining on their posterior end, which is defined 
as the end of the cell furthest from the kinetoplast DNA network (Figure 3A). 29% of 
these parasites have an additional region of staining located between the parasite nucleus 
and anterior pole (Figure 3B). In general, immunoEM studies yield results consistent with 
what is seen by fluorescence microscopy, with antibody labeling present on the parasite 
surface as well as labeling a ring of electron-dense material at the parasite’s posterior 
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pole (Figure 3C & D). However, the T18 reactivity detected between the anterior pole 
and the parasite nucleus that was seen by fluorescence microscopy was not detected by 
immunoEM studies. 
There are very few reports of organelles at the posterior end of L. major amastigotes. One 
candidate for the structure recognized by mAB T18 is the “megasome”, a lysosome-like 
organelle that has been described in New-World Leishmania species such as L. 
amazonensis. This organelle, which is found near the posterior end of these parasites, has 
been reported to degrade host MHC class II (10, 11). However, in electron micrographs, 
amastigote megasomes do not resemble the electron-dense rings seen in our images, and 
instead appear to be large, mostly open, vacuoles containing some electron dense material 
(10). Thus the structure/region recognized by T18 may define a cellular structure that has 
not been described previously. 
Efforts to identify T17 and T18 antigens 
The localization patterns of the antigens recognized by T17 and T18 are sufficiently 
interesting to warrant studies directed towards the identification of the molecules 
recognized by these antisera. One challenge is that Jaffe reported that these antisera do 
not identify parasite molecules in western blotting (2). He did show that they were able to 
immunoprecipitate several amastigote molecules, and from labeling studies inferred these 
were proteins (2). Another challenge is the generation of sufficient amastigote lysate for 
these studies, as isolation of lesion amastigotes from mice is costly, labor intensive, and 
often results in substantial contamination with molecules of host origin. Unfortunately, L. 
major does not give rise to culturable axenic amastigotes, despite efforts by our or other 
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laboratories.  Previous work and preliminary studies I performed suggest that these 
antibodies do not cross-react with amastigotes from other Leishmania species (2), 
precluding the use of ‘axenic’ amastigotes from species such as L. tropica, L. 
braziliensis, L. mexicana or L. donovani as a source of antigen. As such, an approach in 
which the expression of the T17 and T18 antigens could be expressed by parasites in the 
absence of host cells would be extremely beneficial.  
To simulate conditions under which L. major might differentiate into amastigotes, we 
diluted stationary-phase parasite cultures into commercially available RPMI. 24 hours 
later, 40-60% of the parasites presented an amastigote-like morphology (round with no 
visible flagella) and were reactive with T17 and T18 (Figure 4) and were “positive” for 
some of the other amastigote differentiation markers described in Chapter 2 (data not 
shown). Interestingly, the use of other media conditions which had previously be shown 
to successfully to induce other Leishmania species such as L. donovani to differentiate 
into amastigote-like forms and support their subsequent replication (11) was much less 
successful at inducing T17 and T18 reactivity. 
In collaboration with Igor Alameida’s lab at the University of Texas El Paso, these 
conditions are being employed to generate large batches of cells expressing the T17 and 
T18 antigens. Lysate from these parasites will be subjected to immunoprecipitations with 
the two monoclonal antisera with the ultimate goal of antigen identification by MS. If 
these experiments are successful, reverse genetic experiments will be conducted in our 
lab to generate parasites that are unable to synthesize the molecules recognized by T17 
and T18, which will be used as tools to help ascertain the function of these molecules in 
the parasite life cycle. 
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Figure legends 
Figure 1. Localization of T17 reactvitiy. A-C) PEMs that had been infected for 3 days 
with L. major were fixed as described in methods. A) Infected cells were stained with 
rabbit antisera that recognize parasite histones and mouse mAB T17. Primary antibodies 
were detected with Alexafluor488-conjugated anti-mouse antisera (green) and 
Alexaflour555-conjugated anti-rabbit antisera (red). DNA was stained with Hoechst 
33342 (blue). Images were captured using wide-field fluorescence microscopy, scale bar 
represents 2 µm. B-C) Immuno-electron micrograph of infected PEMs stained with mAB 
T17, in which T17-reactivity is indicated by silver granule deposition. Scale bar 
represents 0.5 µm. Abbreviations: N = parasite nucleus, K = kinetoplast, A = flagellar 
axoneme, P = posterior end. 
Figure 2. T17 reactivity is seen in the cytoplasm of infected host cells. A) Confocal 
micrograph of uninfected PEMs (left) or PEMs that had been infected for 3 days with L. 
major. Samples were stained to detect parasite histones (red), the T17 antigen (green), 
and DNA (blue). Bright green punctate staining is absent in uninfected PEMs, but present 
in some infected PEMs. B) T17 reactivity is primarily on parasite flagella, but also 
appears to exit phagolysosome and enter PEM cytoplasm at the flagellar distal tip. C) In 
this image, T17 reactivity is primarily on the parasite flagella and surface (upper left hand 
corner) but also within a membrane-bound compartment within PEM cytoplasm (arrow). 
Scale bar represents 0.5 µm. Abbreviations for B and C: N = parasite nucleus, K = 
kinetoplast, A = flagellar axoneme. 
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 Figure 3. Localization of T17 reactvitiy. A-C) PEMs that had been infected for 3 days 
with L. major were fixed as described in methods. A) Infected cells were stained with 
rabbit antisera that recognize parasite histones and mouse mAB T18. Primary antibodies 
were detected with Alexafluor488-conjugated anti-mouse antisera (green) and 
Alexaflour555-conjugated anti-rabbit antisera (red). DNA was stained with Hoechst 
33342 (blue). Images were captured using wide-field fluorescence microscopy, scale bar 
represents 2 µm. B) Confocal slice of a parasite as stained in (A) showing surface and 
posterior labeling with mAB T18 (DNA labeling is not shown). Intracellular staining 
between the nucleus and the anterior end of the parasite is also visible. Scale bar 
represents 2 µm. C-D) Immuno-electron micrograph of infected PEMs stained with mAB 
T18 in which T18 reactivity is detected by silver granule deposition. C and D) Zoomed-in 
image of parasite posterior. Arrows indicate the amastigote-specific structure recognized 
by mAB T18 and arrowheads indicate surface labeling. Scale bar represents 0.5 µm. 
Abbreviations: N = parasite nucleus, K = kinetoplast, FP = flagellar pocket. 
Figure 4. Induction of T17 and T18 reactivity in axenic culture. Representative images of 
stationary-phase parasites that had been subjected to 37˚C in RPMI media for 24 hours 
and stained with rabbit antisera raised against L. major histone proteins (red) and either 
mAB T17 (left) or mAB T18 (right) shown in green. Scale bar represents 5 µM.  
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